COMPOSITIONS AND METHODS COMPRISING VIRAL REVERSE TRANSCRIPTASE

Abstract

Compositions and methods for making cDNA from RNA templates, including double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA), are provided. The composition and methods include a recombinant or purified or modified or recombinant RNA dependent RNA polymerases (RdRp's). The RdRp has an amino acid sequence that shares identity to a contiguous segment of the amino acid sequence of one or more Partitiviridae virus RdRps, and includes a reverse transcriptase (RT) domain. Kits including dNTPs for use in generating cDNAs are included. The RdRps can function efficiently at lower temperatures than previously available RT enzymes. Methods of making cDNAs are provided using an RdRp are also provided. RdRps can also be used to identify candidate reverse transcriptase inhibitors.

Claims

1. A purified or recombinant RNA dependent RNA polymerase (RdRp) that has reverse-transcriptase (RT) activity for use in producing cDNA from RNA, wherein the RdRp optionally comprises a purification tag.

2. The purified or recombinant RdRp of claim 1, wherein the RdRp is present in or provided with one or more buffers comprising deoxyribonucleotide triphosphates (dNTPs), and wherein the dNTPs optionally comprise all of deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), and deoxythymidine triphosphate (dTTP), and wherein the one or more buffers are free of added Uridine-5-triphosphate (UTP).

3. The purified or recombinant RdRp of claim 1, wherein the RdRp comprises the purification tag.

4. The purified or recombinant RdRp of claim 1, wherein the RdRp is present in a buffer that comprises dATP, dCTP, dGTP, and dTTP,

5. The purified or recombinant RdRp of claim 4, wherein the RdRp is in a complex with a double-stranded RNA or single-stranded template.

6. The purified or recombinant RdRp of claim 5, wherein the complex of the RdRp and the dsRNA template further comprises a segment of a cDNA that is complementary to one strand of the dsRNA template.

7. An expression vector encoding an RdRp of claim 1.

8. A cell comprising an expression vector of claim 7.

9. An in vitro method for producing a cDNA comprising contacting an RNA template with an RdRp of claim 1 such that the cDNA is produced.

10. The method of claim 9, wherein the contacting the RNA template with the RdRp is performed in a reaction buffer comprising dATP, dCTP, dGTP, and dTTP.

11. The method of claim 10, wherein the contacting the RNA template with the RdRp is performed at a temperature of 10-25 C.

12. The method of claim 10, further comprising separating the cDNA from the reaction buffer, and optionally determining the sequence of the cDNA.

13. The method of claim 10, wherein the cDNA is generated in a one-step RT polymerase chain (PCR) reaction.

14. The method of claim 10, wherein the cDNA is generated in a two-step RT PCR reaction.

15. The method of claim 10, wherein the RNA is separated from a biological sample prior to producing the cDNA.

16. The method of any one of claims 9 15 claim 9, wherein the RNA is double stranded RNA.

17. A method comprising: a) contacting a plurality of distinct test agents divided into separate reactions chambers with an isolated or recombinant RT of claim 1, a dsRNA template, and a reverse transcriptase reaction buffer, b) allowing the test agents to be in contact with the RT, and subsequently, c) measuring of cDNA produced, wherein determining less cDNA relative to a control indicates the test agent is a candidate for use in inhibiting reverse transcriptase activity of the RT.

18. A kit comprising an RdRp of claim 1, wherein the kit further comprises one or more buffers that comprise dATP, dCTP, dGTP, and dTTP.

19. A recombinant or purified RdRp optionally comprising an expression tag, wherein the RdRp has an amino acid sequence that is at least 90% identical to a contiguous segment of the amino acid sequence of a Partitiviridae virus RdRp, wherein the contiguous segment comprises a reverse transcriptase domain.

20. The recombinant or purified RdRp of claim 19, wherein the contiguous segment spans at least 50 amino acids of the Partitiviridae virus RdRp.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0012] FIG. 1. Purification of Pepper cryptic virus 1 (PCV1) and demonstration of RT activity A. lane M, molecular weight marker, 1, purified PCV1 virions. B. M, molecular weight marker, 1, PCR product from commercially available MMuLV-generated cDNA; 2, water control; 3, PCR product from PCV1-generated cDNA.

[0013] FIG. 2. Aggregated PCV1 particles (A), likely due to the use of polyethylene glycol (PEG) in the preparation. Improved preparation with no aggregates (B).

[0014] FIG. 3. Image confirming recombinant RT protein expression. Expression was performed using a commercially available vector sold under the tradename pSUMO Vector. The sequence adds a 6 His Tag to the protein and a so-called small ubiquitin-like modifier which can be removed by protease digestion after purification by a 6 His tag, which is also added to the protein during recombinant synthesis.

[0015] FIG. 4. RT-PCR products using Zea mays chrysovirus 1 as a template, and primers for the RdRp gene. The following were used as reverse transcriptase: M, marker lane. 1, PCV1 virions; 2, Pseudogymnoascus desctructans partitivirus-pa (PdPV-pa) virions; 3, MMuLV RT (New England Biolabs). Expected size band is 500 nt (upper band in gel).

[0016] FIG. 5. RT-PCR product from in vitro translated PCV1 RdRp, using PCV1 dsRNA as template and primers for the RdRp gene. M, marker; 1, 1 l of in vitro translation product; 2, 2 l of in vitro translation product; 3, MMuLV RT (New England Biolabs).

DESCRIPTION OF THE DISCLOSURE

[0017] Unless defined otherwise herein, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0018] Every numerical range given throughout this specification includes its upper and lower values, as well as every narrower numerical range that falls within it, as if such narrower numerical ranges were all expressly written herein.

[0019] The disclosure includes all polynucleotide sequences (RNA and DNA) encoding the RT of this disclosure. Cells comprising such polynucleotides are also included, as are all methods of making the polynucleotides and cells. Every possible DNA and RNA sequence encoding polypeptides disclosed herein are encompassed by this disclosure.

[0020] The present disclosure relates generally to a discovery made by our analysis of persistent viruses that are low titer viruses found in fungi and many plants, including crop plants. They are not transmitted horizontally, and remain in their hosts for thousands of years through nearly 100% vertical transmission. Through sequence analysis of a member of the Partitiviridae infecting fungi we discovered a domain in the RNA dependent RNA polymerase (RdRp) that had similarities to an RT conserved domain. A comparison of RT domains is provided in the Table below. Our analysis revealed that all of the RdRp genes from known partitivirus sequences we examined, including those infecting plants and fungi, have these conserved domains. However, and without intending to be constrained by any particular theory, it is believed that there has been no previous analysis of the potential RT activity of these enzymes because to date they are all found associated with viruses with dsRNA genomes. It seems likely, and again without intending to be limited to any particular interpretation, that any potential RT activity in these enzymes has remained undiscovered because these understudied viruses are not usually thought to be very important, and because there is no apparent reason why a dsRNA virus would ever need an RT, let alone preserve an RT domain over such a long evolutionary history. In addition partitivirus-like sequences are found integrated into the genomes of some plants and fungi, although no mechanism for how they were converted to DNA has been demonstrated. These observations, taken together with our sequence analysis, lead to the present demonstration that a partitivirus RdRp does indeed function as an RT.

[0021] In more detail, Pepper cryptic virus 1 (PCV1) is a plant persistent virus in the family Partitiviridae. PCV1 is found in all Jalapeo peppers. Since the pepper host of PCV1 is easy to grow, and PCV1 is generally a relatively high titer persistent virus, we selected this virus for further studies. We also compared PCV1 from different cultivars of hot pepper, including the presumed progenitor of all hot peppers, chiltepin. Chiltepin can be found as a wild plant in Mexico, but it is also consumed locally as a spice, and it is grown in tended areas or in gardens. Given the lack of horizontal transmission of persistent viruses, it is most likely that PCV1 has been consistently infecting chiltepin and domestic hot peppers for thousands of years, diverging with the divergence of their hosts. For most RNA viruses, thousands of years of divergence would lead to changes in the genome that might render them too different to be confident of their common origin, but in PCV1 the difference between the virus in Jalapeo peppers and in chiltepin is only 3%. Once again without intending to be restricted to any particular interpretation, these observations indicate that the RdRp of PCV1 has unusually high fidelity (i.e., a lower error rate) which supports an expectation that RT fidelity of the PCV1 RdRp, as well as other RT's described herein, will be unusually high as well.

[0022] Additional description of the isolation, demonstration of RT activity, and recombinant production of a PCV1 protein comprising an RT is presented in examples and figures of this disclosure. Additional demonstrations of embodiments of the disclosure are also provided using Pseudogymnoascus destructans partitivirus-pa (PdPV-pa) RdRp. Further, specific and non-limiting examples of a wide variety of RdRP proteins that comprise RT domains are provided, and include members of distinct virus genera, but all in the same family (Partitiviridae). In particular, representative RdRP sequences from Group I, II, III, IV and V (genera Betapartitivirus, Alphapartitivirus, Deltapartitivirus, Gammapartitivirus, and unclassified partitiviruses, respectively) of the Partitiviridae family are provided.

[0023] Based at least in part on the demonstrations of making and using RdRPs from two distinct dsRNA viruses, it is contemplated that any RdRp that is isolated from and/or produced recombinantly and/or/derived from any dsRNA virus that has an RdRp which comprises an RT domain will be suitable for use as an RT in embodiments of this disclosure. In certain examples the RdRp that comprises the RT domain is from a dsRNA virus that infects fungi or plants. In embodiments the RdRp that comprises the RT domain is from an encapsidated dsRNA virus. In embodiments the RdRp that contains the RT is a member of one of the Amalgaviridae, Birnaviridae, Chrysoviridae, Cystoviridae, Megabirnaviridae, Partitiviridae, Picobirnaviridae, Reoviridae, or Totiviridae families of plant or fungal viruses. In embodiments, the RdRp that comprises the RT domain is from a dsRNA virus that infects pepper plants. In an embodiment the RdRp that comprises the RT domain is from a dsRNA that is a PCV-1 or Pepper cryptic Virus 1.

[0024] In one non-limiting demonstration of an embodiment of the present disclosure, an in vitro translation of an RdRp and use of the translated RT to produce cDNA from a dsRNA template is demonstrated using a PCV1 RdRp that comprises SEQ ID NO:1, which is meant to be illustrative but not limiting. SEQ ID NO:1 is:

TABLE-US-00001 (SEQIDNO:1) MVRGTLVGYDYTQFQGDLVKSTHRHPHVVHREIATTYVDQYAYEHIET FSSLYPELILKGWSRSYYLPEKHLAAVLNYSMPNVPASQLSQSLYRQA IESAKNGFISLPRVKAFDVLTEMDQVPFKSSSSAGYNYTGRKGLIGDE NHSRAISIAKAVLWSAIKDDGEGIEHVIRTSVPDVGYTRTQLTDLLEK TKVRQVWGRAFHYILLEGLVAYPFIQTVMSHKTFIHAGQDPLISVPRL LSDVALNCKWIYSLDWSQFDATVSRFEIHAAFDIIKSYVDFPNYETEQ AFEITRQLFIHKKVAVPDGYIYESHKGIPSGSYYTSLVGSIINYLRIN YLWRLLTGHPPQQCHTLGDDSLVGDNSYVNPQAIEEAANKLGWHFNPD KTQYSTVPEEITFLGRTYVGGLNKRDLTKCIRLLVYPEYPVESGRISA YRAKSIAQDAGGLSEVLNRIADKLRRIYGTASEEEVPIYFKRYVFGV.

[0025] This sequence is available under GenBank accession no. AEJ07890.1. Conserved RT domains in SEQ ID NO:1 are shown in bold, with highly conserved amino acids shown in enlarged font.

[0026] Conserved RT domains were identified by comparison of the PCV1 sequence to other viral proteins, as shown in the following Table:

TABLE-US-00002 Ty3RT 106 .[94]. XADTFRDLR FVNVYLDDILIFSES P .[4]. KHLDTVLERLKN ENLIVKKKXCKFA 253 PCV1RdRp 185 .[150]. INYLWRLLT .[5]. QCHTLGDDSLVGDNS Y VNPQAIEEAANK LGWHFNPDKTQYS 389 CAEVRT 210 .[100]. MQEILEDWI .[6]. QFGIYMDDIYIGSDL .[1]. I .[4]. EIVKDLANYIAQ YGFTLPEEKRQKG 370 BLVRT 41 .[101]. LQEPLRQVS .[6]. LLVSYMDDILYVSPT E .[4]. QCYQTMAAHLRD LGFQVASEKTRQT 201 Tf2-1RT 455 .[94]. INTILGEAK .[2]. HVVCYMDDILIHSKS E .[4]. KHVKDVLQKLKN ANLIINQAKCEFH 604 RTBVRT 1128 .[98]. MQESFGDLK FALLYIDDILIASNN E .[4]. EHLKIFFNRVKE VGCVLSKKKSKMF 1379 GrpIIRT 115 .[133]. LDGLEALLA .[17]. NYVRYADDFIITGES K .[5]. QVLPVVRRFMAE RGLMLSPEKTKIT 319 Ty3RT 254 .[1]. EETEFLG .[3]. 264 PCV1RdRp 390 .[3]. EEITFLG .[3]. 402 CAEVRT 371 .[1]. YPAKWLG .[3]. 380 BLVRT 202 .[1]. SPVPFLG .[3]. 212 Tf2-1RT 605 .[1]. SQVKFIG .[3]. 615 RTBVRT 1380 .[1]. KEVEYLG .[3]. 1390 GrpIIRT 320 .[3]. EGFDFLG .[3]. 332

[0027] In the Table the following abbreviations are used: Ty, gypsy-like element from yeast; PCV1, Pepper cryptic virus; CAEV, Caprine arthritis encephalitis lentivirus; BLV, Bovine leukemia virus; Tf2-1, fungal retrotransposon; RTBV, Rice tungro bacciliform virus (pararetrovirus); GrpII, Group II intron from E. coli.

[0028] In the Table, sequences for the amino acid segments for each viral RT or RdRp sequence, from left to right including consecutively the top and bottom panels for each virus are as follows: for Ty3 RT, SEQ ID NOs:4-8; for PCV1 RdRp, SEQ ID NOs: 9-13; for CAEV RT, SEQ ID NO:s 14-18; For BLV RT, SEQ ID NO:19-23; for Tf2-1 RT, SEQ ID NO:s 24-28; for RTBV RT, SEQ ID NOs: 29-33; and for GrpII RT, SEQ ID NOs: 33-38.

[0029] In another demonstration of a non-limiting embodiment, isolated virions of Pseudogymnoascus destructans partitivirus-pa (PdPV-pa) (a Group IV partitivirus), comprising an RdRp with an RT domain to produce cDNA from a dsRNA template is demonstrated. The PdPV-pa RdRp comprises SEQ ID NO:2, which is:

TABLE-US-00003 (SEQIDNO:2) MEVSPFDPTPLDNVIEGSPLVDDSLLVPSSRTRGSSYDVIPEHFNSPGLT EIARYGGYPVYSGGSNTDAWVRTSLKEFDRTMYENIYGYTRKPEGPQGMY KSLLKFSEDKSTFHSLNRVQRRAMIGAIKKARTAFKLPWKREPLDWHEVG QFLRRDTAAGATFMGKKKGDVMEEIYHEARWLGHRMKQDGREKFNPKKMR FPPCLAGQRGHMSERDTPKTRLVWVYPAEMLCVEGFYAPQMYRDFMNDRH TPMLNGKSSQRLYTEWCVGLREGEKLYGLDFSSFDSKVPSWLIRVAFDIL RQNIEWSTFRGEKVSKREAQKWRNVWDAMVYYFINTPMLMPDGRMFRKRR GVPSGSWWTQMIDSVVNYILVDYLTQCQTCQIRGLRVLGDDSAFRSCHDF SLDQASADAAAVLMILNPDKCEVTLDPTKFKLLGTTYEDGHPHRETIDWF KFALYPESSVSSIDVSLTRLVGLWLGGGMWDLHFCKFMDYFQTCFPCPLE GWFSKDQRRWLEVIFSGKAPRGWTTKKSLFWHSIFYTYC.

[0030] When given the benefit of the present disclosure, conserved RT domains in any of the RdRp amino acid sequences presented herein can be identified using for use in embodiments of the invention, using for example, a domain identification approach described in Marchler-Bauer A et al. (2017), CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.Nucleic Acids Res.45(D)200-3, the description of which is incorporated herein by reference. In certain instances an RdRp that comprises an RT domain is referred to herein as an RT.

[0031] The disclosure includes amino acid sequences that are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% similar, or identical to amino acid sequences presented herein, and/or to the RT domain of such sequences, such as across the entire length of the RdRp protein, or the RT domain. Additional representative RdRp proteins that comprise RT domains are described below and are encompassed within this disclosure. In embodiments a protein of the disclosure has any of said similarities over a contiguous segment of the sequence that contains the RT domains. In embodiments the protein comprises or consists of any amino acid sequence described herein, or comprises or consists of an RT domain present within any such amino acid sequence. In embodiments, an RdRp and/or RT domain of this disclosure comprises one or more of its amino acid residues substituted with conserved amino acid residues. In certain examples more than one amino acid change can be included. Such changes can comprise conservative or non-conservative amino acid substitutions, insertions, and/or deletions, provided the modified sequence retains or improves on the capability to catalyze the reverse transcription process. In embodiments amino acids substitutions may be substituted with conserved amino acids identified in the RT domain alignment shown in the Table. In embodiments, the disclosure provides recombinant or isolated or modified proteins that comprise RT activity and are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identical to the sequence:

TABLE-US-00004 (SEQIDNO3) [00001] [00002] [00003] [00004] [00005] [00006] [00007] [00008] [00009] [00010] whereinXisanyaminoacid.

[0032] SEQ ID NO:3 is a consensus sequence of partitivirus RdRps. Residues in gray highlighting are conserved among all members of the family of RdRps that have RT-like domains. The residues in bold are domains conserved among a wide range of RTs. In embodiments, the disclosure includes an RdRp with RT activity that is from 415 to 756 amino acids in length, inclusive. In embodiments, a protein of this disclosure is from 600-650 amino acids in length, inclusive. In embodiments, a protein of this disclosure is from 550-610 amino acids in length. Proteins of such length can be at least 90% similar to any segment of any amino acid sequence presented herein. In one embodiment an RdRp with RT activity of this disclosure has at least 90% identity with SEQ ID NO:3 over its entire length, and in embodiments, includes any one or any combination of the amino acid sequences GDD, XRPL, SXFD, PSGX, wherein X is any amino acid, within the protein. In an embodiment, the RdRp with RT comprises the GDD sequence. In embodiments, an RT of this disclosure has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity across the contiguous segment of SEQ ID NO:3 spanning amino acids 395-465, inclusive.

[0033] Any protein provided by this disclosure can be modified such as by being engineered to include a leader or secretory sequence or a sequence which can be used for purification e.g., a His-tag, and/or to include a proteolytic cleavage site. In a non-limiting embodiment the protein is engineered to comprise a ubiquitin segment and a protease cleavage site for removal of the ubiquitin segment. Modifications can be made at the N-terminus, C-terminus, or within the protein. Such modifications can be made using known reagents and techniques, given the benefit of the present disclosure.

[0034] In certain approaches the DNA or RNA sequence encoding a protein of this disclosure can be altered from a naturally occurring sequence, such as by optimizing codons for expression in any particular expression system. In certain approaches a polynucleotide sequence encoding a protein of this disclosure is modified by incorporation into any suitable expression vector, shuttle vector, plasmid, etc., as further described below and demonstrated in non-limiting examples. In certain approaches expression vectors, such as plasmids, are used. A variety of suitable expression vectors known in the art can be adapted to produce the proteins. In general, the expression vector comprises sequences that are operatively linked with the sequences encoding the protein, such as promoters, transcription initiation and termination signals, origins of replication, sequences encoding selectable markers, etc.

[0035] The disclosure includes methods of making the RT proteins. Such methods generally comprise either isolating virus that comprises the RdRp from the host where it is found normally and using isolated particles for performing reverse transcription, or by producing the protein recombinantly. Producing the protein recombinantly generally comprises initially introducing an expression vector encoding the RdRp into any suitable host cells by any method known in the art. Methods vary depending upon the type of cellular host, and include but are not limited to transfection employing cationic liposomes, electroporation, calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances as will be apparent to the skilled artisan. In certain embodiments the cells used to produce the protein recombinantly are prokaryotes, including but not necessarily limited to E. coli, but eukaryotic cells may also be used, including but not necessarily limited to plant, fungal, insect and mammalian cells. The methods include allowing for a period of time during which the protein is expressed in the cells, and then separating the protein from the cells, after which the protein can be purified to any desired degree of purity. As discussed above, the proteins may be engineered to contain segments that improve protein expression, secretion, separation and/or purification.

[0036] In general, methods of this disclosure comprise combining incubating a fully or partially double-stranded RNA template, or a single-stranded RNA template with a purified or recombinant protein of this disclosure, such that a cDNA of at least one of the strands of the RNA template is produced. The method can optionally further comprise isolating the cDNA, and if desired determining or confirming the sequence of the cDNA. The RT and the RNA template can be combined in vitro to perform one or a plurality of cDNA assays. The RT could also be used to produce a cDNA copy of an RNA within a cell.

[0037] In certain embodiments, the disclosure includes generating a cDNA as described herein and determining the sequence of the cDNA. The sequence of the cDNA can be recorded in any tangible medium of expression. In embodiments, a plurality of cDNAs are determined and are compared to one another and/or to a database. In embodiments, the disclosure includes determining the sequence of a cDNA produced from dsRNA or ssRNA from, for example, a virus, and deducing an amino acid sequence encoded by the cDNA. In embodiments, cDNA sequences from cDNAs produced according to this disclosure are from, for example, retroviruses. In embodiments, cDNAs produced according to this disclosure are from samples comprising members of Reoviridae, such as rotaviruses, which comprise dsRNA genomes. In embodiments, cDNAs are produced from samples comprising influenza virus, including Influenza A, B or C viruses. In embodiments, cDNAs produced by amplification of all or a segment of an influenza virus single stranded RNA molecule are used to deduce the amino acid sequence of hemagglutinin (HA) and/or neuraminidase (NA) encoded by the viral genome. Thus, embodiments of this disclosure are suitable for generating genetic information that may be useful in predicting viral outbreaks, and/or for vaccine design. Furthermore, generating cDNA as described herein may be useful in diagnostic applications, such as to provide information about a viral infection in a human, or a non-human animal, or a fungus, or a plant, or a protist, or a bacteria or archaea. Further still, population studies (and other experimental analysis) of RNA viruses are limited by the error rate of the enzyme used for analysis, such as previously available RTs. These studies are critical for understanding virus evolution, including projected evolution of human pathogens such as influenza A virus, that is required for deciding on the specifics of future vaccines. Thus, the lower error rate that is expected to be produced by using an RdRp comprising an RT function as described herein provides advantages that are applicable to numerous applications.

[0038] Using an RT of this disclosure to produce a cDNA can be advantageous in a variety of techniques wherein determination of the presence, absence, amount, nucleotide sequence of a strand of an RNA, or combinations thereof would be useful. In this regard it is expected that any RNA can be used as a template for cDNA production using approaches of this disclosure, and there will be no particular upper limit to the bp length or other constraints on nucleotide composition, other than those imposed by the availability of reagents (i.e., dNTPs) to continue the reverse transcription process. In certain approaches, a fully or partially double-stranded RNA template is analyzed by cDNA production using an RT of this disclosure in a cell-free in vitro assay, or in an in vitro assay comprising cells. In the performance of such assays fully or partially double-stranded RNA templates will be in physical association with an RT of this disclosure, thus forming a complex comprising the RT and a dsRNA. The dsRNA may be in physical association with more than one RT of this disclosure at any particular time, and depending on the length of the dsRNA template distinct RTs may be concurrently generating cDNAs from the same dsRNA template in an anti-parallel direction. Those skilled in the art will recognize that a dsRNA template that is being reversed transcribed by an RT of this disclosure may include a segment that is in physical association with the RT but is not itself double-stranded due to the presence of a transcription bubble, wherein the strand being reverse-transcribed is transiently separated from its complementary strand in order to catalyze cDNA synthesis. Thus, the disclosure includes complexes comprising an RT as described herein, wherein the RT is in a physical association with a fully or partially double-stranded RNA template, and wherein the RT is also in physical association with a DNA polynucleotide (e.g., a cDNA) that is being synthesized during the process via RT activity.

[0039] In one embodiment the disclosure provides for determining the presence, absence and/or the sequence and/or the amount of a segment of RNA that is in a dsRNA configuration by exposing a sample comprising or suspected of comprising dsRNA with an RT of this disclosure, along with suitable reagents that are typically employed in a Reverse-Transcription PCR (RT-PCR) approach, and after a period of time determining the presence, absence, and/or sequence and/or amount of the cDNA. In an embodiment, by comparison to a suitable control, the absence of cDNA is a basis for inferring a lack of dsRNA in the sample, whereas the presence of cDNA indicates the presence of dsRNA in the sample. In an embodiment the method comprises comparison of ssDNA in the sample with a control reaction that is performed using a portion of the sample and a standard RT, many of which are commercially available, and include Moloney murine leukemia (M-MLV) and Avian Myeloblastosis Virus (AMV) RTs. Determining a difference in ssDNA relative to the control permits determining ssDNA production that it is attributable to the RT component of the RdRp acting on a dsRNA template, whereas the standard RT would not use the dsRNA as a template. Determining the sequence of a cDNA, if present, provides for identification of the sequence of at least one strand of dsRNA that was the template for cDNA synthesis, which also permits deduction of its complementary strand. Generating and determining the sequence of cDNAs is well known in the art, and the present disclosure includes performing this process, but with substitution of the RT of this disclosure for any of the well-known commercially available reverse transcriptase enzymes typically employed in RT-PCR reactions.

[0040] Generating cDNAs using an RT of this disclosure can be performed in a one-step RT-PCR, or a two-step RT-PCR. As will be recognized by those skilled in the art, a one-step RT-PCR reaction entails generating a cDNA using the RT, and PCR amplification of the cDNA in a single reaction container. Two-step RT-PCR entails the reverse-transcription reaction being performed in a single reaction chamber to obtain single-stranded cDNAs, which are then separated from the reverse-transcription assay and PCR-amplified in a separate reaction chamber. In certain approaches specific temperature parameters are included to avoid denaturing the RT. In certain approaches the methods of this disclosure include reverse-transcription cDNA generation at a temperature of less than 50 C. In embodiments, cDNA generation is performed at a temperature of less than 40 C. In embodiments, cDNA generation, i.e., producing cDNA by an RT of this disclosure, is performed at a temperature of from 10 C., to room temperature, wherein room temperature can range from 20-25 C. In embodiments, the only application of heat to generate a cDNA according to this disclosure is to temporarily denature dsRNA structures for the purpose of annealing primers. In this regard, those skilled in the art will recognize that at room temperature, currently commercially available and other previously characterized reverse transcriptase enzymes, would not be able to synthesize cDNA from a dsRNA template because the dsRNA renatures, which is not a suitable template for a non-RdRp reverse transcriptase. The kits of this disclosure described below can be adapted for either approach. Further, these approaches can be tailored for quantitative purposes.

[0041] In embodiments, an RT of this disclosure has a reduced error rate for nucleotide incorporation into the cDNA, compared to a control, such as a commercially available RT. In embodiments, the control comprises an error for reverse transcription by M-MLV virus reverse transcriptase. In embodiments, the control comprises an error rate for AMV reverse transcriptase. In embodiments, a control error rate ranges, from 1 error for every 17,000 bases to 1 error for every 30,000 bases. The error rate can be applied to a plurality of cDNAs. In embodiments, a cDNA of this disclosure can comprise from 500 nts to 12 kb in length. In embodiments, generation of a cDNA as described herein is performed without using any methyl mercury, such as methylmercury hydroxide. In embodiments, cDNA according to this method is performed without use of any reverse transcriptase obtained or derived from a bacteria, including but not necessarily limited to Thermus aquaticus. In embodiments, a cDNA generated according to this disclosure does not include an A-overhang. In embodiments, a cDNA according to this disclosure is generated without using any RNAase H.

[0042] It will be recognized from the foregoing that the present disclosure provides flexible approaches for detecting the presence, absence and/or amount of ssRNA or dsRNA by virtue of detecting the presence, absence and/or an amount of cDNA. Those skilled in the art will appreciate that as described above, this approach can be adapted to test any biological sample for dsRNA or single stranded RNA, which can be a critical step in detection and/or discovery of viruses, as well as other dsRNAs that may be present in a biological sample. Other dsRNAs from which cDNAs may be generated according to this disclosure can include double-stranded segments of RNA polynucleotides present in RNA secondary structures found in ssRNA virus genomes, mRNAs, tRNAs, snoRNAs, miRNAs, siRNAs, shRNAs, etc. Accordingly, in certain approaches an RT of this disclosure can be used for direct dsRNA sequencing and for instance, for RNA secondary structure mapping.

[0043] In certain approaches an RT of this disclosure can be used for screening a plurality of test agents to determine if they are candidates for use as an RT inhibitor, including but not necessarily limited to an RT that is a component of an RdRp. In general, the method comprises analyzing test agents using any system wherein the production of cDNA from dsRNA can be measured. In one embodiment, the method comprises screening a plurality of test agents to identify candidates for use in reducing RT activity by: a) contacting a plurality of distinct test agents (which may be divided into separate reactions chambers, such as in a high-throughput screen) with an isolated or recombinant RT of this disclosure in the presence of an RNA and RT-PCR reagents; b) allowing the test agent to be in contact with the RT for a period of time, and subsequently, c) measuring cDNA, wherein determining less cDNA relative to a control indicates the test agent is a candidate for use in inhibiting the RT. The presence and/or amount of the cDNA can be determined using standard approaches.

[0044] In an embodiment the disclosure provides a kit comprising an isolated or recombinant/modified RT as described herein. The RT can be provided as a single component or with other components, and can be included in or more sealed vials. The kit can include any reagents required for performing one-step or two-step RT-PCR, including but not limited to amplification buffers, one or more primers, nucleases, and dNTPs, including deoxyadenosine dATP, dCTP, dGTP, and dTTP. In an embodiment, an RdRp comprising RT activity is present in or provided with a buffer, such as a reverse transcriptase reaction buffer, which may comprise added dNTPs. The dNTPs need not include added nucleoside triphosphates that contain ribose as the sugar (NTPs). In embodiments, a buffer or other reaction component of the disclosure does not include uridine-5-triphosphate (UTP) because the kit and other aspects of the disclosure are designed for DNA synthesis only. Thus, the kit and/or buffer includes dTTP instead of UTP. Accordingly, the disclosure includes buffers to which no UTP is added. In embodiments, the only nucleosides added to a buffer used in embodiments of this disclosure are dNTPs. In embodiments, the only nucleosides in a buffer or other reaction component of this disclosure are one or more dNTPs, and thus a buffer of this disclosure may include a nucleoside or nucleotide component which consists of, or consists essentially of, one or more dNTPs.

[0045] The dNTPs may be provided in any suitable molarity, such as from 1-20 mol. In an embodiment, the dNTPs are provided in 8 mol solutions. The kit may optionally include instructions for performing the RT that are either written on paper or in a computer-readable format.

[0046] In an embodiment, the RT is in a lyophilized form, and the kit further includes instructions for reconstituting the RT for use in cDNA production.

[0047] Additional representative RdRp amino acid sequences that comprise suitable RT domains are as follows:

The Following Representative Amino Acid Sequences are from RdRps from Group I Partitiviruses (genus Betapartitivirus)

TABLE-US-00005 Atkinsonellahypxylonvirus (SEQIDNO:39) MSTLLIPQDTIAHTFDEAVASESNLRIDEVPENYLERFIHPSEPENFEFYSLRDSDIPSKRIPKNGIQVFENLKYHTNSKD NLYKDQPSSGPSPMRGVANIIREYFPQYLDDLRTWCRPKSSDDSIFNDFNHEQRITQPFTEERERRLLPLIDHFLGIKPYD IVHYCDTRFYPWKLSTRADYFHNHSRDRKAHAAKSHPDFATGPTKKSYFINSHLFFDRSTVHNIKEYGFPFRPTTDSARNE TLLDLWFKKVPTELLVRSHISKRDNLKVRPVYNAPMIYIRIECMLFYPLLAQARKRDCCIMYGLETIRGGMNELERISNAF NSFLLIDWSRFDHLAPFTISNFFFKKWLPTKILIDHGYAQISNYHDHVHSFSAQAQSHGIPMISKEYQTPPEATVFAKKVL NLISFLERWYRDMVFVTPDGFAYRRTHAGVPSGILMTQFIDSFVNLTILLDGLIEFGFTDEEIKQLLVFIMGDDNVIFTPW TLLKLIEFFDWFAKYTLDRFGMVINISKSAVTSIRRKIEVLGYTNNYGFPTRSISKLVGQLAYPERHVTDADMCMRAIGFA YASCAQSETFHALCKKVFQYYFAKTSINERLILKGRKAELPGMFFAYPDVSEHIRLDHFPSLSEVRILLSKFQGYLKETPF GTIPTFSTPQTLRDQTQ CannabiscrypticvirusFedora (SEQIDNO:40) MPYNAVRNYLAERMIRTKREWQLYQSSNRDPESTLEHYQDSDYLRYYQNARFNLNQEERFRALNKEYSTLVEAFRTDNLRK HQPYELHQPIPPDAAPIPDKRQPAPGIKLVPLMYHYGHVVHDTPSTTDDHTSNDDSQSAPSRLLKTTEFGYSIDKQIYDLV CRRYPTYLSVINLYCRPLGTVDATFSDFNKEQIPSNPIDPDRKEHVLKHIFKFLDATPYLPVHFVDTQFCKTPLVTGTGYH NRYSFKQKAHAKYSHPEEYATYPSSKGYFYNATYENARTLVHYIKQNGLPFEFDFNLSEESLTDEQIDLFVNRSNAFFNDY PTLLFTRNHISKRTGPLKVRPVYAVDDIFIIIELMLTFPLTGQARKPSCWIRMARNHSGSNRYIDRLGRSYSTFFFINWAS YDQPMPRVITDIYYTDFLRSLIVINHGYQPTYEYSFYPDLDEHKLYDRKNNLLFFLHTWYNNMTFLLPDGFAYRRSYCGVP SGLYNTQYLDSFGNLFLIIDAMIEFGFTDSEIDGFVLLILGDDNTGMTQMHIHRISQFINFLEKYALERYNMVLSATKSVL TTLRSKIETLGYQCNYGSPKRDIDKLVAQLCFPENGLKPHTMSARAVGIAYAAAGQDYVFHSFCQDVYNMFRSYYKPDARA NLFFQRQVLQNLEDGIPDLATPVVPPFPSLFEVREMYSEYKGPLSFEPKWNKAHFINDPNDIPPFSKTMRDYEKEHNLPVR VSPTFETVVPSTKNLP CannabiscrypticvirusHemp (SEQIDNO:41) MPYNAVRNYLAERMIRTKREWQLYQSSNRDPESTLEHYQDSDYLRYYQNARFNLNQEERFRALNKEYSTLVEAFRTDNLRK HQPYELHQPIPPDAAPIPDKRQPAPGIKLVPLMYHYGHVVHDTPSTTDDHTSNDDSQSAPSRLLKTTEFGYSIDKQIYDLV CRRYPTYLSVINLYCRPLGTVDATFSDFNKEQIPSNPIDPDRKEHVLKHIFKFLDATPYLPVHFVDTQFCKTPLVTGTGYH NRYSFKQKAHAKYSHPEEYATYPSSKGYFYNATYENARTLVHYIKQNGLPFEFDFNLSEESLTDEQIDLFVNRSNAFFNDY PTLLFTRNHISKRTGPLKVRPVYAVDDIFIIIELMLTFPLTVQARKPSCCEVIYGFETIRGSNRYIDRLARSYSTFFSLDW SSYDQRLPRVITDIYYTDFLRSLIVINHGYQPTYEYSSYPDLDEHKLYDRMNNLLFFLHTWYNNMTFLLPDGFAYRRSYCG VPSGLYNTQYLDSFGNLFLIIDAMIEFGFTDSEIDGFVLLILGDDNTGMTQMHIHRISQFINFLEKYALERYNMVLSATKS VLTTLRSKIETLGYQCNYGSPKRDIDKLVAQLCFPENGLKPHTMSARAVGIAYAAAGQDYVFHSFCQDVYNMFRSYYKPDA RANLFFQRQVLQNLEDGIPDLATPVVPPFPSLFEVREMYSEYKGPLSFEPKWNKAHFINDPNDIPPFSKTMRDYEKEHNLP VRVSPTFETVVPSTKNLP Crimsonclovercrypticvirus2 (SEQIDNO:42) MPFNAVRNYLNERMTRLKQEWKTYQSTDHDPIKILDTIQDPDYRRYLDNARFNSDNEMKHLMLNKEYSTLVEAYRTDNAKK HQVYELHQPIPNDAAPVIQSRLPAKGIKLVPLMYHYGHVTHDPVSLTDANRSDDFETQVVPDSDAPTRFGYPIDVRIYNLI CYRYSKYLEVINAYCRPIGTVNATFEDFNKEQIPSAPIDPKRKENVLSHIHKFLDTKPYLPLHFVDTQFCKTPLVTGTGYH NRYSFKQKAHAKYSHPAEYATKPISKGYFYNATYENARTIIHFIKEYGLPFNVIRADDKSELTDSDVQKYINEANSFFNDY PTLLFTRNHISKRDGPLKVRPVYAVDDIFIIMELMLTFPLTIQARKPSCCEVIYGLETIRGSNRYIEQIARDYSTFFSLDW SSYDQRLPRVITDIYYTDFLRSLLVINNGYQPTYEYPTYPDLDEHKLYHRMDNLLHFLHLWYNNMTFLLPDGYAYRRTSCG VPSGLYNTQYLDSFGNLFLIIDAMLEFGFTDSEIQKFILLVLGDDNTGMTTIPICRMFNFITFLEKYALERYNMVLSTTKS VLTTFRSKIESLGYQCNHGSPKRDIDKLVAQLCYPENGLKPHTMAARAIGIAYASAGQDDMFHSFCQDVYNIFRSDYRPDD RMNLHFKRQIFHNLEDGMPDLAPPIVPPFPSLYEIREMYAYYKGPLDFAPKWNYAHFMSDPDTTPPYSKTMRDYEAENNIS SRVAPTFETVVPSTINLP Ceratocystispolonicapartitivirus (SEQIDNO:113) MPSFSANPTYQTLIDDIDFDVPIAHPFSVINTDLQPVDDEETVHDLGSKDFEFYKVVSDNLPPTRAPSIGIESLPNIRYHN HSNDHRYRDQPPTGPPPMRGVRKIINDSFPQYLPYLKEWCRPKTSSDAIFEDFNQPQIPSIPLSYNRKQRILNLVNHFMGV KPYDIVHFCDTRFYPWDLSKKADYFHNHSNARKRHAQTSHASTATGPTKKSWFINAHLFHDRSTVHNIKLYGLPFKPHSYE ARNKILLELWFKKIPTELLVRSHISNPKKLKVRPVNNAPMIFLRIECMLFYPLLAQLRKQQCSIMYGLETIRGGMMEIESL ATRFSNFMMIDWSKFDQTVPFTLVDMFYQDWIPTLILVDSGYAKIHNYNDHVHSFAAQARKLGVHGDSNLNEAPPEAAVFA NKVENLLKFINTWFKEMVYITPDGFAYSRTFAGVPSGILCTQLIDSFVNLVVLIDSLFEFGFHESDIKSALILLMGDDNVV FAPDKLSQLHSFFKFLPDYAKKRWNMKVNVDKSIFTTLRRKIEILGYTNNYGMPVRSLSKLIGQLAYPERHVNDSDMCMRA IGFAWCAAASDSTFHDFCRKVFIYYYARVNVPIKDLVQSNASALPGMFFAYRDVHQHIKLDHFPSIEEVRQVLSKHHGYLT EEPLWKYDFFLHPKP Ceratocystisresiniferapartitivirus(SEQIDNO:43) (SEQIDNO:43) MPSFSANPTYQTLIDDIDFDVPIAHPFSIINTDLQPVDDEETVHDLGSKDFEFYKVVSNDLPLNRAPSVGIESLPNIRYHN HSNDHRYRDQPPTGPPPMRGVHRIINDSFPQYLPYLKEWCRPKTSSDAIFEDFNQPQIPSIPLQHSRKQKILKLVNHFMGV KPYDIVHFCDTRFYPWDLSKKADYFHNHSNARKRHAQTSHASTATGPTKKSWFINAHLFHDRSTVHNIKLYGLPFKPHSYA ARNKILQELWFKKIPTELLVRSHISNPKKLKVRPVNNAPMIFLRIECMLFYPLLAQLRKQQCSIMYGLETIRGGMMEIESL ATRFSNFMMIDWSKFDQTVPFTLVDMFYQDWIPTLILVDSGYAKIHNYNDHVHSFAAQARKLGVHGNSNLNEAPPETAIFA NKVENLLKFINTWFKEMVYITPDGFAYRRTFAGVPSGILCTQLIDSFVNLVVLIDSLFEFGFHESDITSALILLMGDDNVV FAPDKLSQLHSFFLFLPGYAKKRWNMTVNVDKSIFTTLRRKIEILGYTNNYGMPVRSLSKLIGQLAYPERHGFDSDMCMRA IGFAWCAAACDSTFHDFCRKVFMYYYARVNVPIKDLVQANASALPGMFFAYRDVHQHIKLDHFPSIEEVRQVLSKHHGYLT EEPLWKYDFFIHPKP Fusariumpoaevirus1 (SEQIDNO:44) MLANIRDYFHEKLTRLLYDHKIFQSNSKDPDLTLEAHHSSDIERIYKSIHYDFNRSPAPIDYEAQYQSIKHILEDKQSQQG FPHEYYRLHESPIPDDRIPPSGIKLLPFEYKSMNVVTATPEVPESGFKIHPRIERLLRSKYPQYLQYVRKYTRPLGTTNAT VSDFFKPQTPSQPVEPTRINHVMSHVMKKMAITPYLPLHFVDTQYDKRPLANGTGYHNRRSHEMNIHALFSHPKEYESKRT SKGYYVNAFLESARSLIHWIKLYGNPFRHCPSDLAQSLREFFLQRPTMLFTRNHISDRDGILKQRPVYAVDDLFLTIESML TFPAHVIARKPECCIIVIYGLETIRGSNQILDKIASDYKSFFTIDWSGFDQRLPWVIVKLFFTEYIPRLLVVNHGYAPTYE YPSYPDLTTNDMVSRLTNLITFLATWYFNMVFVTADGFSYVREHAGVPSGMLNTQFLDSFGNLFLLIDGLIEFGSTDAEID DILLFIMGDDNSAFTTWSITHLEQFVSFFETYALSRYGMVLSKTKSITTTLRHKIETLSYQCNFGHPRRPIGKLVAQLCFP ERGPRPKYMSARAVGMAWASCGQDKTFHDFCRDVYHEFNDDRADLDESAYLHIQSHLPGYLKIDESVRQIVDFQVFPSQQT VYHTVSRWKGPLSYQPEMGSCSLCQPT Heterobasidionpartitivirus8 (SEQIDNO:45) MLSKVRDFFHEKLSRLLLQHSIFQSNDKDEEQTLLENQSSDVKRIYNSIHYSFQTDDTQAAYEDQYQHIKHVLEDKDRLSN FPAEFYLPYDTTTTPDNRVPPSGIDQLPYVYKRTNVVTATDEVPETGYPIQNRLLRLIRSRYPQYLPHVRTFTRPLGTTDA TVSDFFKPQHPSRLVDPSRISHVMKHVMNKMAITPYLPIHFVDTQYDKRPLSTGTGYYNRRSHEANIHALYSHPKEYENKR TSKGYYINAFLESARSLVHWIKSYGNPFRSKPADPRESLKKFFLQRPTMLFTRNHISKILGALKQRPVYAVDDLFLTLESM VTFPAHTIARKIECCIIVIYGYETIRGSNVQLDRLAQRYNSFFTIDWSGFDQRLPWVIVLLFFTEFLPRLLVINHGYAPTY DFPSYPDLTTEMMYQRLSNILSFLATWYFNMVFITADGFAYVRRFAGVPSGLLNTQFLDSFGNLFLIIDALIEFGAQDEEI DSILLLIMGDDNSGFTIWSIARLEQFITFLESYALTRYGMVMSKTKSLVTVLRHKIQTLSYTCNFGRPLRPIPELVAHLVF PEREFKPQFMSARAVGMAWASCAQDKTFHDFCRDVFYEYLEESVPVDNTNIAWIQSHLPGYLRVDPEVTKMIDLNVFPSFL HVSQKLSRWQGPLSYQPKWDLAHFINQPDVIPDDSITMFEYMQEHSLSLDIQFDLFSA Hoptrefoilvirus2 (SEQIDNO:46) MPFNSVRNYLEERSVRVKKEMMTYQSSNRDPDAILEQSQDPDYRRYYDNARYNPSNDLKYRMLSKEYSTLVEAYRLRNDDK HQPYELHQPVPQDAAPVPSYRAPAPGIKPVPLMYHYGHVIHDPVSLTESAIDDDSDTLPDSDEPTVTHFGYPINKRIYDLI CNRYPEYLSVISAYCRPIGTVDATFKDFNKEQIPSGPIDPNRKEEVLTHIFRFLDAQPYLPLHFVDTQFCKTPLVTGTGYH NRYSFKQKAHAKYSHPEEYAQMPTSKGYFYNATYENARTLVHYIKEYGLPFNIHYTPEDVDFTEEQIQAYIDSANNFFNDY PTLLFTRNHISKRDGTLKVRPVYAVDDLFIIIELMLTFPLTVQARKQSCCIMYGLETIRGSNHYIERLARSYSTYFSLDWS SYDQRLPRVITDIYYTDFLRRLIVINDGYQPTYEYPTYPDLDEHKMYTRMDNLLTFLHTWYNNMTFVLADGYAYRRTYCGV PSGLYNTQYLDSFGNLFLIIDAMIEFGFRTPEIDDFILLVLGDDNTGMTVISIDRIYDFITFLEIYALTRYNMVLSTTKSV LTTLRSKIETLGYQCNHGSPKRDISKLIAQLCYPENGLKPHTMASRAIGIAYASAGQDYMFHSFCQDVYNMFRLDYKPDAR TTLNFQRQIYHNLDDGIPDLATPVVPPFPSIFEVREMYSRYQGPLTYAPKWNFAHFINSPDVTPAHYKTMRMYEIENNITI RPAPTFETVVPTTRNFP Lentunulaedodespartitivirus1 (SEQIDNO:47) MVFQQIRDFLSERKLRIQEEWRRYQKAVSRDDTELRQSDASDIRRMYEATRDQLTEQEKAAVLDREFQGLIDSMLLKNENK KENFEFSSTSAFDGFPPNRVPISGIAGIPRRFHTGQIVSESNEVPESGYPLDTLIDTLITNKYPEYRYYVDKYTRPLGTTD ATFKDFNKEQVLIEPLDSARKERVMMHVHERLATTPYLPIHFVDTQFCKLPLHTGTGYFQRHSFWTQTHSKYSRPEEYHDR PTSKGYVMNAFLILARTAVHKIKVSGLPFDFDFDDFEDDNAAFNELAKYLDKFLNDHATMLFTRNHISQRDGKLKQRPVYA VDDLFILIEAMLTFPLLVLARDPACCIMYGLETIRGSMIYIDQISRMFNSFATIDWSEYDQHVPRPITDVYYYEFLPDLIV INHGYQPTYEYPTYPDLDEHAMYKRIDNLLFFLHFWYNNMTFVTADGYGYRRKHCGVPSGLFNTQYLDSFGNTYLIIDGLC EFGCSDEEIRLFLIFVMGDDNSLMSYWTLERLIAFIQFFEAYAKMRYNMTLSRTKSTLTAVRSKIEMLGYQCNFGRPSRPI GKLVAQLCYPERGLFRKFMSYRAIGVAYASAGIDVKFYKFCKDIYFTYLPYAVAASEFNFLRAATHLPGYLKAFDDVSDYI NFEKFPTIYEIREVYSYYHGPLSYEPKWNRAHFINRPNIVPPSAKTVGDYRRENNLQPRQVPILPTD Primulamalacoidesvirus (SEQIDNO:48) MPFNAVRNYLAERLVRVRTELKNFTSSNREPDATLELSQDPDLRRYYDNTRYNSSNDAKYRTLNKEYSTLVEAYRTDNQQK HQPYELHQPIPADAAPIIDKRQPAPGLKLVPLMYHYGHVIHDPDPDQPDQTKVYPLDSRIYNLIMSTYPSYLSVLHDYCRP IGTVEATFNDFNTEQIPSAPIDEDRKQQILKHLFKFLDVKPYLPIHFVDTQYCKTPLVTGTGYHNRYSFKQRAHAKYSHPE EYALKSTSKGYFYNATYENARTLVHLIKTYGLPFNMQFACPKSDLTDEQINLYISKANQFFNDYPTLLFTRNHISKRSGTL KVRPVYAVDDIFIIIELMLTFPLTIQARKPSCCIMYGLETIRGSNHYIDRLARPYSTFFSLDWSSYDQRLPRVITDIYYTD FLRSLIVINHGYQPTYEYPTYPDLDEEIKLYSRMDNLLYFLHTWYNNMTFLLPDGYAYRRTHCGVPSGLYNTQYLDSFGNL FLIIDAMIEFEFTDDEISKFQLLILGGDNTGMTNLAIDRIDKFITFLETYALARYNMVLPKTKCILTSLRSKIVTLGYECN YGSPKRDIHKLVAQLCFPENGLKAHTMSARATGIAYASAGQDIMFHSFCQDVYNIFRSDYKPDVRANLYFQRQFLNDLEEG VPDLATPTVPPFPSLYEIRKLYSKYQGPLSFTPKWNSAHFINEPDSVPISAKTMRQFEEEFSIPLMTAATFETVVP Pleurotusostreatusvirus (SEQIDNO:49) MSFLRIRDYFTERLKHLSRDWKIFQQSDSDPESTLATHLDSDIARLEHGIKSSLSDDQRQQAYEREYNRIHSALHDKARQD GFPDEFYRSRSIDDLPDNRIPPSGIIPLPYEYHRSQVVISTEEVPETGFQIDPRIVRILRNKYPQYLPHVTKYVRPLGTTD ATVKDFFKPQIPSDPIPEARKQRILDLVISFLACTPFLPLHFIDSLWDKTPLHTGTGYFNRHSFAARIHAMFSAPRLYERR TTSKGYFINYFLETARSTIHNIKLHGFPFDPSKVPDLGSALRSFILKRPTMLFTRNHISDRDGNLKQRPVYAMDDLFIRLE SMITFPLHVMARKIECCIMYGYETIRGSNRQIDKIASSFRSFFTIDWSGFDQRLPRVITDIFWSDFLERMIVISHGYQPTY DYPSYPDLTPDKMFQRMDNILFFLHTWYNNLVFVTADGFAYIRTCAGVPSGLLNTQYLDSFSNLFLIFDGLIEFGCSDAEI YQIFLLVMGDDNSAFTLWSIAKLEEFLSFFESYALRRFGMVLSKTKSVITVIRGKIETLSYQCNYGAPKRPLAKLVAQLCY PERGPRAKYTSARAIGMAYAACAMDRTFHDLCRDIYYEFLDDSASPDEPFFFEHVQAYLPGILRTDESLSTQISLSSFPSF LTVQQHISRWQGPLSYYPKWDRAHFINDPDVIPPSAETMAEYRSRNSIPRRDIPSLWQ Redclovercrypticvirus2 (SEQIDNO:50) MPFNSARNYLAERMIRTKQELMTYQSEDHNPDAILEKSQDPDYRRYYDNTRFDPSNEVKHRILNKEYSTLVEAYRIKNDRK HQPYELHQPIPEDAAPIPESRVPAPGLKLVPLMYHYGHIVHDPVASESDSDDDNTASERPSKTSIPHFGYPVNKRIYDVIV NVYPEYLKVIGEYCRPIGTVEATFADFNKEQIPSAPINIERKEQVLTHIFKFLDAQPYLPLHFVDTQFCKTPLVTGTGYHN RYSFKQKAHAKYSRPEEYAKLPTSKGYFYNATYENARTLVHFIKQFGLPFNLQYAPEDADPTDEQVQSYIDTANSFFNDYP TLLFTRNHISKRDGTLKVRPVYAVDDLFIIIELMLTFPLTVQARKQSCCIMYGLETIRGSNHYIERLARSYSTYFSLDWSS YDQRLPRVITDIYYTDFLRRLIVINHGYQPTYEYPTYPDLDEHKLYSRMNNLLYFLHTWYNNMTFVLSDGYAYRRTHCGVP SGLYNTQYLDSFGNLFLIIDAMLEFGFSESEIDNFILLVLGDDNTGMTVISIDRIYDFINFLEKYALIRYNMVLSPTKSVL TTLRSKIETLGYQCNHGSPKRDISKLVAQLCYPENGLKPHTMAARAIGIAYAAAGQDPMFHSFCHDVYNLFRLDYKPDART NLNFQRQIYHNLEDGIPDLATPVVPPFPSLYEVRHMYSKYQGPLSYAPKWNYAHFINDPDVTPPSPKTMRDYEIENDLISR TAPTFETVVPATRNFP Rosellinianecatrixpartitivirus1-W8 (SEQIDNO:51) MVLTIIRDYLHEAQLRLKKEWQTFQKSDQESGYSDKLPTDYDLRRYYDSARDYDAEKHKTEEYQHNFALTHERYTQMNADR NEPFEFYRPLEDNELPDIRFPAPGITVLPFRYHTGQIVETTDELPDSGFSLHPLIDYLTKTKWLHYRPYIDKYCRPLGTTN ATFSDFNREQIPSAPIDETRKNMVLPLVIYFLNALPFLPIHFVDTRFCGTPKHTATGYFQRFSTFFRTHAYYARNKLYALR PTSKGYFFNTVYEFSRTWMHHIKEHGYPFVPSHDALDNARQYRIFMQKHVTMLFTRNHISDRDGFLKQRPVYAVDDFFILC ELMISFPLHVMARYPINGIKSCIMYSFETIRGSNRYLDSIARDFISFFTIDWSSFDQRVPRVITDIFWTDFLRQLIVINHG YQPTYEYPAYPDLSEHDLYKRMNNLLHFLHTWYNNMVFVTADGFAYLRSAAGVPSGLLNTQYLDSFCNLFLIIDGLFEFGF TQAEILSIVFFIMGDDNSGFTMMDIERLTQFIEFFESYALKRYNMVLSKTKSVITTLRSRIETLSYQCNGGNPKRPLGKLI AQLCYPEHGPKDKYMSARAIGIAYAAAAMDEEFHEFCRDIYHTFLPYAAPIDEHTLSMATKHLPGYFKMLDNIASEIKFDS FPTLEMVQDKYSRWQGYLSHKPKWNDAHFKFLPETVPNNIKTMTDYQLEHKLDTPVPHSLF Rosellinianecatrixpartitivirus6 (SEQIDNO:52) MSSVFNNVRNYLQERLQHVKREWQIYQATGASSSNMTEERIQQLQDLDTRRMFHTARNAFDTTTNTPGPVSRITEEQRRLI YDAESDKIMNALRQHDEMRSQPFELFMTRPDSDPIPPNRIAAPGIWQSPLQFHTGQIVHADPSTTSVLHPDEHEDYAESYL PGDTDQGYEIDPTIYELLTRKYPEYLPYAQQYCRPKGTTDGTFRDFNKEQKPCPPLDSDRKEHVLKHVFKRLAIDPYLPLH FVDTQYCKLPLVTGTGYHNRYSYRQKAHASFSHPLQYGSRPTSKGYFYNATYENARTIIHNIKESGVPFNIHFAPEDRDIT DTEIDEYRRKCNNFFDQYPTLLFTRNHISNRDGTLKVRPVYAVDDIFIIIEAMLTFPALVQARKPDCCIMYGLETIRGANH KLDSLAQSFSTYFTIDWSGYDQRLPRAITDLFYTDFLRRLIVISHGYQPTYEYPTYPDLNEDNMYDRMDKLLKWLHLWYNN MTFVTADGYAYRRMYAGVPSGLFNTQFLDSFANLYILIDGMIEFGFTDEEIDSFLLFVLGDDNSGMTNLSLARLHEFIQFL EAYALTRYHMVLSHTKSVITALRNKIESLGYQCNFGLPKRDIGKLVAQLIYPEEIKIKYHTMSARAIGLAYASCAYDKTFY NFCKSIYNIFLDYYEYDEKTALNLSRFLTTGQDDLTTQFSWKILPPFPTREEIRKQISFYHGPLDYAPKWNFAHFINKPDV IPPSSKTMYDYEIEHSLRPQPAPTFVAR Sclerotiniasclerotiorumpartitivirus1 (SEQIDNO:53) MDSIRNIFQELRQTNVLEWKLFQKFGQTTTNPTYSHPDADLRRIQETFRDPHLERSQTQEFKLHYTDTYSGFRESDLSKNE DFEFYKPIDPSSIPASRLPAPGISVLPIRTHAEQVITATEQVPETGYQLHPLLRHLIVSKYPLYMQHATKLCRPLGTTDAT FDDFNREQKQYPPIEPELALRIVRIIIHLLYALPFLPLHYIDTFFCKMPLHTGTSYFYRHSYELRTHVAFSAPSEYENKQT SKGYFFNAFTSWARTVAHRIKEFGYPFDPTQLTPSEITDKLRSFFMEHATMLFTRNHISDRDGALKQRPVYAMDTLFLHLE AMITFPLHVLARSSRSAIMYSMETIRGGCARMDALASSCQSYLCIDWSSFDQRMPWIIVDLFFTLFLPLLLIISHGYQPTA EYSEYLGLTPDKMFSRLFNIISFLRLWYYNCVFVTADGYAYVRRFAGIASGMLNTQYLDSFCNLFLMIHALLHFGCTNEEI LDFIYFVMGDDNVILTQWTIDRLFSFLTFFESHSLSRFGMVISTKKSVITSLRSRIEMLGYQCNCATPKRPISKLVAQLCY PEHGPNDKYMSSRAVGMAWASAGYDAEFFAFCKDVHTLFTPFAAPPSEQTTQTILKHLPGLFKMLDDVTEFTNPQAFPDIM TVRNRYATWQGELSPDKKWSRAHFLRRPDDTPLPFQTMFEYMSEHGITFPEPQQLF Whiteclovercrypticvirus2 (SEQIDNO:54) MPHNSTRNYLAERMIRTKRELMTYQSKDRDPDAILEASQDQDYRRHYDNARYDPSNEVKYRILNKEYSTLVEAYRLRNDRK HQPYELHQPIPEDAAPIPKSRVPAPGLKLVPLMYHYGHVVHEPAHSDESDSDDNSDAPTRPVKESVPHFGYPVSKKIFDLI VRVYPEYIKVINTYCRPLGTVEATFADFNKEQIPSAPINSKRRETVLKHIFKFLDTQPYLPLHFVDTQYCKTPLVTGTGYH NRYSFKQKAHAKYSHPEEYAKMHTSKGYFYNATYENARTLVHFIKQFGLPFNLQYAPEDADLTDDQVQSYIDAANNFFNDY PTLLFTRNHISKRDGTLKVRPVYAVDDIFIIIELMLTFPLTVQARKQSCCIMYGLETIRGSNHYIERLARSYSTFFSLDWS SYDQRLPRVITDIYYTDFLRSLIVINHGYQPTYEYPTYPDLDEHKMYSRIDNLLYFLHTWYNNMTFVLSDGYAYRRTHCGV PSGLYNTQYLDSFGNLFLIIDAMLEFGFSDAEIDDFILLVLGDDNTGMTVIPIDRIYDFINFLEKYALVRYNMVLSPTKSV LTTLRSKIETLGYECNHGSPKRDISKLIAQLCYPENGLKPHTMAARAIGIAYAAAGQDFMFHSFCHDVYNIYRLDYKPDAR TNLNFQRQIYHNLEDGIPDLATSVVPPFPSLYEVRHMYSQYQGPLTYAPKWNYAHFINDPDDVPPNPKTMREYEIENDLIS RTAPTFETVVPATRNFP
The Following Representative Amino Acid Sequences are from RdRps from Group II Partitiviruses (genus Alphapartitivirus)

TABLE-US-00006 Amasyacherrydisease-associatedmycovirus (SEQIDNO:55) MDHLTSLFELFAITPKTQNNLQFVGIYHRPPHSVRANLRNVEKHKITVAHAMHKYLYPHEIDFVINQMRRSDVTEDAILAD FFDNNVEPLEPVLDEHFERGLSAMLDAFRPPQKCLPAHIYDVQHHYPYKWQVNAEAPFSTDSYFLANRPTFRAVFERLESL YTHLATDWHRRYGNKTDNDDFMNDHVPAKFGPMKETVFSWTHRWHHVIKSNFTDTAGLSKDYYFKNRYIFPMLLHTKTAIV KKDDPNKMRTIWGCSKPWIIADTMLWWEYVAYAKLQPGATPMLWSYETFTGGWLRLNHALFSSYIRHSYITLDWKRFDKKA YFCIIDKIFDGVETFLDFDNGYLPTKDYPDTKSTWTQERSTRLKRLFDWTKENFYHAPIVLPNGHMYVRKFAGIPSGLFIT QLIDSWYNYTMLATILSAMGFDPRSCIIKVQGDDSIIRLSALIPPDAHDSFLTKVQELADYYFQSVVSVNKSEVRNELNGC EVLSYRHRHGLPYRDELAMLAQLYHTKARNPSPEITMAQSIGFAYASFGNHERVRLVLHDIHEYYKLQGYTPNRAGLSLVF GNSPDLMIPHYTLDHFPSLREIKMFLTNAEYVNEETNSRTWPLNHFLHLPCHRT Arabidopsishalleripartitivirus1 (SEQIDNO:56) MKNTVVLEPLPSLARPIYGDTDPGRNPAYQSTVDHALRRLLTAEEFNIVVNGYRRSPWNEDALTADIEKLNSDYHHVNKDE HYYKAIEHTKKLFTPKEKLRPVHFNDLRHYPWQLSTSIGAPFATSEKWKDYINQKYDGKLKSRDFKDLFKETHGVSLEPYM IDRRLSKRNFYNEMFYINRINIHHIKDGWTTNPAGHDLRYWHTAHARQHLVEAGDEDKVRLVFGAPSTLLMAELMFIWPIQ TSLLARGSSSPMLWGYETTTGGWSRLYNWAYSALPRFGAVATLDWSRFDKDARHTVITDIHDLIMRPMFDFNSGYHPTIIN PRSNPDPQRLENLWNWMKNAILTTPLLLPDGTRLQFQHSGIYSGYFQTQILDSMYNCVMIFTVLSRMGFDLNSVAIKVQGD DSLILLSHSYTFLQHSFLTTFAHHAAVYFGSTLNVKKSELLPSLEDAEVLRYRNHGMMPYREELQLLAMLRHPERTASLSA LMARSIGIAYANCGNYTRVHHICEDIHNYLKGIGVKPDAFGLPGGLRFRKNYLPSYEEIDISHFPTWLETVERLLDPSRPL LTNKHWPTTHFFGIPGES Beetcrypticvirus1 (SEQIDNO:57) MDYLTSAFNRITHWFNVPSNLEYIGTFSLPPGILRVNEVAISNHKKTLEHSFNKYLYAHEIKLITQDYRRSDIDEESILAD FFSGDVEKFEVPFDEHVETGLRCMADAFRPPRLCRPAHILDVKHGYPYKWNVNAEPPFSTDEYFLNQRKTFGEFIRMHEYE HIDKADFFRRHPNTESHDLIRTIVPPKFGYLKSMIFSWTRRWHHIIKEGFTESTGLHTTGYFYNRFIFPMLLHTKTAIVKQ DDPNKMRTIWGASKPWIIAETMLYWEYIAWIKLNPSVTPMLWGYETFTGGWFRLNRDLFCGFLQRSFLTLDWSRFDKRAYF PLLRRILYTARTFLTFDEGYVPTHSAPTHPQWDHTKAIRLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATLLSALGFDPKHCIIKVQGDDSIIRLNVLVPQDQHQNLMDNLVQLAVNYFNAVVNVKKSEFGNSLNGREVL SYRNHNGFPHRDEIMMLAQFYHTKARDPTPEITMAQAIGFAYASCANNKRVLWALKDVYDYYKDLGYTPNRAGLTLTFGDS PDLFVPEISLEHFPTETEIRRYLTSTSYLNEAQNARTWPRTLFINAPAQ Carrotcrypticvirus (SEQIDNO:58) MDYLTTAFNRITHWFTTPTDFEYIGNFSLPPGLLRVNDTAISNHKKTLEHSFSKYLCADEIHLITKEYRRSDIDLDSILDD FFSGDVEKFEIPFDEHVETGLRCMADAFRPPRLCRPAHILDVKHHYPYKWNVNAEPPFSTDEYFLTQRKTFGEFIRMHEYE HIDKADFFRRHPNHESHDLLQTIVPPKFGYLKSTIFSWTRRWHHVIKDGFKDSSGLQTNGYLYNRFIFPMLLHTKTAIVKH NDPNKMRTIWGASKPWIIAETMLYWEYIAWIKLNPGTTPMLWGYETFTGGWFRLNHQLYCGMIKHSFLTLDWSRFDKRAYF PLLRRILYPVRSFLTFDEGYVPTHAAPYHPQWNHEKALRLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATILSALGFDPKQCIIKVQGDDSIIRLTVLIPQETHERFMAULTHLATYYFNAIVNVKKSEVANTLNGREVL SYRNHNGFPHRDEINMLAQFYHTKARDTTPEITMAQAIGFAYASCGNHNRVLWVLNDIYNYYKDQGYSPNRAGLTLTFGDS PDLFVPEIPLDHFPTKKEIRRYLTASSYINEAQNARTWPRDLFINRPAE Dillcrypticvirus1 (SEQIDNO:59) MDYLTTAFNRITNWFTKPANFEFVGLYSLPPGLLRVNDTAISNHKKTLEHSFSKYLYEDEIHLITKEFRRSDIDLDSILDD FFSGDVEPFEIPFDEHVETGLRCMADAFRPPRLCRPVHILDVKHHYPYKWNVNAEPPFSTDEYFLSQRKTFGEFISMHEYE HIDKADFFRRHPNRESHDLLKTTVPPKFGYLKSVIFSWTRRWHHVIKDGFKDDTGLKTTGYFYNRFIFPMLLHTKTAIVKH NDPNKMRTIWGASKPWIIAETMLYWEYIAWIKLHPSVTPMLWGYETFTGGWFRLNNQLFCGMIKHSFLTLDWSRFDKRAYF PLLRRILYQVRTFLTFDEGYVPTHAAPYHPQWDHEKALRLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATILSSLGFNPKQCIIKVQGDDSIIRLTVLIPHENHLKFMERLTELATYYFNAIVNVKKSEVANTLNGREVL SYRNHNGFPHRDEINMLAQFYHTKARDPTPEITMAQAIGFAYASCGNHKRVLWVLNDIYNYYKDKGYTPNRAGLSLTFGDS PDLFVPEIPLDHFPTTKEIRRYLTCSSYVNEAQNARTWPRTLFLKDPAE Diurispendunculatacrypticvirus (SEQIDNO:60) MEYLIADFSRITHFFRDTTNLTYSGTYHFHPRHPEVNLNAYEAHQRVLRSLMDTHLFPHEIQLITDELRRSDMTIEAILAD FFANDVEYHEIPFDSHIEYGIKCMLDAFRPPKRCRPVHLLDVQHHYPYKWQVNAEPPFSTDTYFLDNLPTYRDFWNERTSS FDKYVDPEELNRRLRHRNIENLLDTKTPAKFGFLKNTVFSWTRRWHHIIKDGFTDTTGLTSDAYLRDRFIFPMLLHTKTAI VKKLDPNKMRTIWGVSKPWIIAETMLYWEYIAYVKQNTGATPMLWGYETFTGGWLRLNAALYTSHVRFSFLTLDWKRFDKK AYFPLIYKILLGVRDFLDFDNGYAPTVDYPDTKSTWTPHKSQRLQNLWLWTIENLFNAPIVLPDGRMYKRRFAGIPSGLFI TQLLDSWYNYTMLASLLSALSMNPKSCIIKVQGDDSIIRLGTLIPPSQHEAFLLKLHALADFYFKASLSLDKSEVRNSLDG CEILSYRHIRGIPYRDEITMLSQFYHTKARNPTPEIAMAQAAGFAYASCGHHRRVYNYLESVYNHYAVQGYTPNRAGLSLV FGNSPDLILPHFELDHFPTISEIQHYYTSSVYRNESQMSKIWPLDHFLYPPAET Heterobasidionpartitivirus7 (SEQIDNO:61) MEYLSNLFSRVLKITKTTNFEFVGTYHNQPSIPQVNQIAIDNHQRTIRVAMERYLTSDEFSLITTGYKRTSLDPATITDDF FSGDIEPHDEPQDLASQLAIEAGLNAMQRAFCPPNPARPVHLYDVEWHYPYKWQVNAEVPFSTETYFLKLRKKFSDFYDAA SKTWTHYVNPLDALRRYGPEPPFDTLNQVTPPKFGFMKELIFSFVHSWLHVIKSRFHSNAGYTHSNFLRQRFLFPMQLHIK TALVKADQPNKLRSIWGVSKLWIIAETMIYWELIAYMKLNRGSTPMLWGYETFTGGWFRLNAELQSSHLRQSITTIDWSRF DKRAYFWLIRKILFRIRQHLDFNNGYVGTKDYPSSPTDPDKLQALWEWTLEALFDSPIILPDGKMYKRRFAGIPSGLYITQ LLDSWYNYTMLAAILTYLGLDPERCIIKVQGDDSIIRLYVLIPPSEHDNFLLKMQEVATHLFASRISDQKSEVRDDLNGAE VLSYRNNRGLPYRDEIQMVAQFYHTKAKDPTPEITMAQAIGFAYAACGNNYRIHSLLEEVYNYYHEQGFTPNPAGLSIVFG DSPDRPDYPIELDHFPTQQETQRFLLSTDYRNAEQDARTWPLLHFLHAPCSRS HeterobasidionRNAvirus1 (SEQIDNO:62) MDYLTGLFSRVLHISRKVTNFEFAGTYHYQPSIPQVNEVATENHKRTLRHSFRTYLTSDEYDKIVNGYKRTNLDPSTITED FFSGDIEDHPEPTDFKSQLSIEYGLQCMIDAFKPPAPARVCHLYDVQWHYPFKWQVNAEAPFSTEKYFLDLRKKFGDFFDP VTKLWTKYVNPLDALRRYGHTPPADTLNQVTPPKFGFMKNLIFSFVHSWQHVIKSRFTSNAGITHSNFLRQRFLFPMLLHI KTAIVSFDAPNKLRSIWGVSKLWIISEAMIYWEYIAWIKLNPGSTPMLWGYETFTGGWFRLWRDLHTPGEDVTYITIDWSR FDKRAYFWLIRKIFIRTRCFLDFTNGYVSTKDYPTSPTDPDKLQALWEWTIEAFFDSPIVLPDGSMFKRLFAGIPSGLFIT QLMDSWYNYTMLAAILHYMGYDPRRCIIKVQGDDSIIRLYIQIPLHEHDLFLLRMQEVSDHLFGAKISFEKSELRNSLIGS EVLSYRNIQGLPYRDLIKMLAQFYHTKAKDPTPEITMAQAIGFAYAACGNDFRIHELLRSVYDYYKAQGFTPNPAGLTVVF GDSPDRPDYPISLDEFPSQMDVQRFFLSTDYRNADQENRTWPSSHFLYAPCSRI Redclovercrypticvirus1 (SEQIDNO:63) MDYFISAFNRITHWFTTPTNFEYVGNYSLPPGLLRVNDVAIANHKKTLEHSFNKYLYSHEIKLITKEYRRSPIDEDSILED FFSGDFEYFEIPFDYHVEYGIQCMADAFRPPRLCRPVHILDVKHGYPYKWNVNAEPPFSTDEYFLSQRKTFGEFIRMHEYE HIDKDDFFRRHPNSESHDLLRTIVPPKFGYLKSMIFSWTRRWHHIIKSGFTESTGLETNGYFYNRFIFPMLLHTKTAIVKK NDPNKMRTIWGASKPWIIAETMLYWEYIAWVKLNPGVTPMLWGYETFTGGWFRLNNELFCGLIKKSFLTLDWSRFDKRAYF PLLRKILHTTRTFLTFDEGYVPTFAAPTHPQWNQEKAHRLDRLWIWTLENLFEAPIILPDGRMYKRHFAGIPSGLFITQLL DSWYNYTMLATILSALHFDPKHCIIKVQGDDSILRLTTLIPVDQHANFMSHVVRLASHYFNSIVNVKKSEVANTLNGREVL SYRNHNGLPHRDEITMLAQFYHTKARDPTPEITMAQAIGFAYASCANHNRVLWVLHDIYNYYHDLGYRPNRAGLTLTFGDS PDLFVPEISLDHFPTKSEIRRYLTALHYQNEAQNARTWPRTLFINAPGE Rhizoctoniafumigatapartitivirus (SEQIDNO:64) MEYLVHAFKMFSLEPSVPQNLQMIGTYHYKPASPHVHTPHVEAHKKTVLKAMEKYLYPREINTIVNELRRSDVNLESILDD FFDNNVPLHRIPFDEHVEYGLQCMADAFRPPRPARPCHLNDVEHHYPYKWQVNAEAPFATDKYFLDNRHKFRDFYDETTGT WKHADPIDMERRYGNRLDTVLDQITPPKFGYMKNAIFAWTRRWHHIIKDGFTDLTGLVSSTYVRDRFIFPMLLHTKTAIVK KDDPNKMRTIWGCSKPWIIAETMLYWEYIAWVKLNPGITPMLWGYETFTGGWLRLNAALFSSLMKNSFVTLDWKRFDKRA YFELIYRIMLVARTFLDFENGYVPNVNYSATHTDWSHTKAQRIQRLWEWTLDNLFNAPIVLPNGDMYKRNWAGIPSGLFIT QLLDSWYNYVMLATLLSALGHDPKACIIKVQGDDSVIRLAVLIPPQYHELFLTRLQDLADHYFGAVISIEKSEVRNELNGV EVLSYKHIHGMPYRDEIAMMAQLYHTKARNPEPSITMAQAVGFAYASCGNHDRVYYALKDIYEYYASQGFAPNPAGLTLVF GNSPDRFELDVPLDHFPTIHEIKKYLLNFEYRNEHQEHKTWPLDYFLNPPCSTL Rosellinianecatrixpartitivirus2 (SEQIDNO:65) MKNITDLPFPSKGVPQFRDALPIHGRDPEVPNPVTDASNRIIDFALRKHLTSDEFDQVVNGYRRSPWNEDALNKDIEKLDS DEHTVIKDQHYENAIQHVQKLLTPEKPLQPVHFADLRRYKWRLSTNIGAPFASSKHWQDYVKAKFNHFRDGTPFENIAHRD LFVEAHKDSQPLEITDARMTKHNLYTEAFYVSRETIHRIKDGETTDRYGNDARYWNTAFARQHLVKADEDDKVRLVFGAPF SLLCAELMFIWPLFIFLLSLKGSTAFMLWTFETIIGGWYRLVNFFTTYALRHSTVVTVDWSGFDRYARHTVIKDIHHRIIR PMFDFSHGYHPTRDYPDTSKTKDGQSNEWRITNLWNWMTDAILSTPLLLPNGRFIRFNHSGIYSGYFQTQILDSIYNLVMI FTILSRMGFDLDKCVIKVQGDDSIFMLLCCFIMISTSFFTLFKYYAEYYFGAKLNEKKSEIRPSLQDAEVLKYRNRNGIPY RDRISLLAQLRHPERRTDVDSVAARCIGIAYAACGQDATVYLICEDIYNYLVKKYDAHARQGELDFMFRHLELHDTVPSAA TFPSWFDTMAHLTDGPRDPVPSHWPTDYFIGLPGRL Rosellinianecatrixpartitivirus7 (SEQIDNO:66) YNVQTAIDAVTEQFRPNRVLHPIQYPDLRYYPWTLNVSAEAPWTSYNFHFVPMDRSVDFESTQPKLIFDINQVNKLRKFSK PTDVKTYLRWKQQVGLIENDHITFHNLYDEIFIYNRPLIHQIKEGEEPFWKDGQPVPYLWNTLHVRSHVVAHNEPDKLRGV FGATKLVLQTEQPFIWPLQASYLNTDAGRLLWGREMSKGGWRKLFSEIYTFGPPSTVLSTDWSQFDKRLLHQLIRIVHRIW RSYFDFTRYEPTNQYPNANPRDPKRLERLWDWMCNAITDTPILLPNGEIWRWQWNGFGSGYQQTQLMDTFANAIMIYTCLT ALGVDVTNPKFWARFQGDDSLVAFFEQMFRIYGNDFLIMFSAVAEKYFNAKLNVKKSSILGQAHMATVLSYPNWHGTAFRT DEDLLRHLMFPERPQDLGRLAASAIGLAQAALGCSERFHNLCEYIFTKLVKGKGVKVKWQALKWMVRAGQFETIEQLKRTE FPTIEELLSQAQIPAIRTESERQRIWRTTPLSKDSFHFTHDI RosepartitivirusPB (SEQIDNO:67) MRNTVVIGHRPVLAKPLFGNPDPGSNPAYGDTVDHALKRHLSPEEFDIVVHKYRRSPWNEDALKDDIAKLDSNEHPVLKDE HYYRAIEHVKKLFTPEEKLRPVHFADLRYYPWQLSSNIGAPFATSKKWQEYVNDKFTAGQTAPQVRNLFQEAHGTPLEPEV IDRRMTKRNLYNEMFLINRKNIHLIKDGRKTNDSGHDLRYWHTAFARQHLVEHDEPDKVRLVFGAPSTLLMAELMFIWPIQ VSLLARGPDSPMLWGYETLTGGWSRLHTWATKAQPRLGSVLTLDWSRFDKDARHTIIKDIHSLIMRPMFTFDNGYHPTVYY PETPETDPNRLENLWNWMTDSILTTPLILPDGKILQFMHSGIYSGYFQTQILDSMYNSVMLFTILSRMGFNIEKVAIKVQG DDSIILMPYQYTVIKDTFLQFFSAYAQEYFGSTLNMKKSEILPSLERAEVLRYRNHGTMPERDELQLLAMLRHPERTSSLP SLMARAIGVAYANCGNHTRVYQICEDIYKYLAKGGFKPDPFGLPGGLRYRQNYIPSYVQ1DISHFPTYFETVMHLQDPHRA ILTNRHWPTDHFIGTPGKS RhizoctoniasolanidsRNAvirus2 (SEQIDNO:68) MNLYNRVSALFANWFSSPSNLEFVGSYHHQPGTVPPNPSTQEAHKRFLHNVFKQHLFTYELDYIENEHRRSEATPEAIEND FFANDVEPHDIPFDVHVEIGLQCMTDAFRPPVPCLPAHLNDVEHHYPFKWQVNAEPPFSTDSYFLDNRKLFSDYYDTESQT WRGYVDPFEANRRYQHTKDKEGFLNQTVPAKFGFMKDTIFSWTRRWHHIIKEGFQTATNLSSTAYLRDRFIFPMLLHTKTA IVKKDDPDKMRTIWGCSKPWIIADTMFYWEYIAWIKKHPGVTPMLWGYETMTGGWMRLNSQLFSSYLKKSYVTLDWSRFDK RAYFKLILAIMCRVRTFLDFDNGYLPNVNYPDTRTDWSPNKAQRLERLWLWTLECLIKSPIVLPDGRMYIRHYAGIPSGLF ITQLLDSWYNYTMICTILSSIGLNPKHCIIKVQGDDSIVRLGVLIPPEAHEAFLLALQSKADFYFKATISVDKSELGNSLN NREVLSYRNYNGLPRRDEIKMLAQFYHTKARNPTPEIAMAQAVGFAYASCGTHQRVLDALEHVYTDYKDAGYTPNRAGLSL VFGNSPDIQLPHYDIDHFPSIEEIKRFLTCNSYDNSVQMAKSWPTSYFISEPCERM Spinachcrypticvirus1 (SEQIDNO:69) MDYLTSAFNRITHWFTKPTNLEYIGDYSTPPSIIRVNEVAIANHKKTLRYAFEQYLYDHEYRMIVDEYRRSDIDQESILAD FFSGDIEPFDIPFDEHVEHGLRCMANAFRPPRPCRPAHILDVKHGYPYKWNVNAEPPFSTDPYFLSQRKTFGEFIQMHEYE HIDKADFFRRHPNTESHDFLTTVVPPKFGYLKSMVFSWTRRWHHVIKTGFQDLTGLENSGYLYNRFIFPMLLHTKTAIVKK NDPNKMRTIWGAPKPWIIAETMLYWEYIAWIKLNSGKTPMLWGFETFTGGWFRLNNILFCGLIKQSFLTLDWSRFDKRAYF SLLRRILYTARTFLTFDEGYVPTHAAPTHPKWNHQKALNLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATLLSALGFDPKYCIIKVQGDDSIIKLTTLIPRDQHENFMVQLTALATTYFNATINVKKSEIRNTLNGCEVL SYKNHNGFPHRDEITMLAQFYHTKARDPTPEITMAQAIGFAYASCGNNKRVLWILRDIYNFYKMRDVTPNRAGLTLTFGDS PDVFMPEIPLDHFPTITEIRRYLTCSEYRNEAQDARTWPRSLFISGPAE Sophorajaponicapowderymildew-associatedpartitivirus (SEQIDNO:70) MASTNLLRLGKIPRSKKHNDPLSRSLRINRIRQGIIKRAIYKICPINLARQVIFGFKRSEGSDDVAETDFLRSDVPYFDMK RDFHYLRALRVCERLFRPSRTLHPIAFPDLRFYPWSLSVSAEAPFSVEKKRSTLIRSRQSDGEDLDGRLTFHNLYNEIFEL NRNLIHQIKEGDKSFWNKDGTPRPYWYNTLHTRPHLVKSSEPDKLRAVFGVPKLLLMAENMFIWSLQKEYLNQKIQSPMLW GFETFKGGWLKIWNRMYSKKCSTFLSADWSGFDRFALFECVDDIHRMWRNWFDFSKYEPTIAESGPPGIQLSYPKSKTNPQ KIERLWNWMCYCSKYTPIKGQSGQLYQWQYNGIASGYQQTQLIGSFVNSIYMLTCLSDLGINIESDNFQLFVQGDDSLTEF SEIIQKDDLPKFLTNLAKVAKSRFNANLSVQKTTAGESLNDVEVLSYNNTYGIAFRDEAELLAHLLYPERFQTLEATVSCC IGIAYASMGCSQYVDDTCLDAYNFLTTQFKVKPDSNFLQDFFRIRGSPLTDDFHNPRFPTKDECFNQNYEVRSRSDSEKQR LWPSIPTGDYGFHFINE SclerotiniasclerotiorumpartitivirusS (SEQIDNO:71) MPALNLRYLFSISRSEMKKIRSSHTKVSPREEATRFSILKHAILKHGSVGLLNQVLLGKRRSDASDERLIQDFHEFEQPVH PVPRDKHYLRALRVTEKLMKPAKTLHPISFPDLRYYPWTKNVSAEAPYNFEKKYEELLRDKQRLGEIETATATFHNLEDEI FEDNRYLIHKIKEGDSQFWDKDGKPRPYYHTTLHARAHVVGHEDADKIRAVFGVPKLLLMAENMFIWPLQAYYLNQDTTKH HLLWGNEIMKGGWKKLWGQLQNGRISRTILSLDWSEFDKRALHEVIDDVHSMWKSWFDFTHYEPTIFYEKGEIPEPHRRIE NLWIWMTDMVKHYPILQPDGKVYQWTRNGIASGFQQTQLLDSFVNMIMLLTVLSANGINIEHPDFWIKVQGDDSLISIVER RFQMFGISYLDTLADLASYYFNAKLSVKKSFISDTPQGQYVLGYFNHYGIPYRLDDDLLSHLVFPERPQRLEETAASCVGI AMASMGCSKVVYSICDDAYTFITKTLRRPAKAGSLFWLERAFGYEMPNIAKMPTFEECLYASYDIPVRTENMKQRLWPTNA KAKNGFYFLRHLC Viciacrypticvirus (SEQIDNO:72) MDYLISAFNRITHWFITPTNFEYIGYFSLPPGLLRVNDVAIANHKCTLERSFHTYLFDHEIKRIMIDHRRSDITEDSILED FFAGDFPYFEVPFDEHVEYGLQCMADAFRPPRPCRPAHILDVKHGYPYKWNVNAEFPFSTDEYFLTQRKTFGEFIRMHEYE HIDKDDFFRRHPNLESHDFLRTIVPPKFGYLKSTIFSWTRRWHHIIKLGFTDTTGLDNNGYLYNRFIFPMLLHTKTAIVKK DDPNKMRTIWGASKPWIIADTMFYWEYQAWVKHNPGSTPMLWGFETFTGGWFRLNQLLFCGLIRRSFITLDWSRFDKRAYF PLLRKIMYTVKSFLTFEEGYVPTHAAPNHPQWNQDKTDKLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATILHALGFNPSNCIIKVQGDDSIIRLNVLVPSERHDHLMSRIVELAEYYFNSIVNVKKSEIRNRLNGCEVL SYRNHNGLPFRDEIAMLAQFYHTKARDPTPEITMAQAIGFAYASCATHTRVLWVLEDIYNYYRDQGYTPNRAGLTLTFGDS PDLTMPEMPLDHFPTKSEIVRYLTCTNYRNEAQNARTWPRTLFINAPAE Whiteclovercrypticvirus1 (SEQIDNO:73) MDYLITAFNRITHWFLTPTNLEYIGSYSLPPGLLRVNDVAVANHKATLDRSFDKYLYEHEINLITKEYRRSPIDEDSILED FFSGDLPYFEIPFDEHVERGLECMAAAFRPPRPCRPAHILDVKHGYPYKWNVNAEPPFSTDEYFLSQRKTFGEFIRMHEYE HIDKEDFFRRHPNIESHDFLRTVVPPKFGFLKSMIFSWTRRWHHIIKSGFQDSTDLEQTGYFFNRFIFPMLLHTKTAIVKK NDPNKMRTIWGASKPWIIAETMFYWEYLAWIKHNPGATPMLWGYETFTGGWFRLNHELFCGLIQRSFLTLDWSRFDKRAYF PLLRRILYTVKTFLTFEEGYVPTHAAPTHPQWSQENIDRLERLWLWTLENLFEAPIILPDGRMYRRHFAGIPSGLFITQLL DSWYNYTMLATILSALHFDPLHCIIKVQGDDSILRLTTLIPVDQHTNFMDHIVRLADTYFNSIVNVKKSEVRNSLNGCEVL SYRNHNGLPHRDEITMLAQFYHTKARDPTPEITMAQAIGFAYASCANHNRVLWVLEDVYNYYRDLGYRPNRAGLTLTFGDS PDLTMPEMPLDHFPTKSEIRRYHTETHY QNEAQNARTWPRTLFINAPGE
The Following Representative Amino Acid Sequences are from RdRps from Group III Partitiviruses (genus Deltapartitivirus)

TABLE-US-00007 Alternariaalternatapartitivirus1 (SEQIDNO:74) MLLSEIPNVYQRALALERRLRLRELYPEGIIPYLARQEYAGSIAGPRGPSATVAPSVTTSF IAKAPLSTYSKPEYTLECTETMQYLGKMDHYAFNNSVPKFDPWFRHVLKSKAPDVVLH LEETYQRDPCTPERVMKFMKLFDRRWKRMPTGNVMKQAKEIVSEMFSKVGKVDPIDF NYAGWHEILPHLDMSSSPGLPLRREYATQGECLGHIYDKTKRLNHFAKFLHPGAVRAPP CMIGLRPGLIKKAEIDEKIKARGVWAYPAEVKVIEMRYCIPLMKRFSEMFGKTPYPVGR NMTKALPFIIDHLLQDKKFGLVTDISKLDTSVGPDWIDWAFSQLKSFFDFGFTLSSERRD SNVFDFLHFYFKRTPILLPSGQLVKKAGGVPSGSGFTQLVDTLVTTLATVYSRLRMGHT KDQIFKMFVVGDDMATSVDHDFSIEEFSHIMGQLGFEINPSKVMFSNKGIELKFLGYSKR GGGLYRPIEELLQTAFFPEKYVGNPNRSRQRILGQSIAAGLSNSFFDKCNYWMEELVTLS STLDPDEVFIPQKRWMRNVLSIDEMPKSANVYDLFHLV Beetcrypticvirus2 (SEQIDNO:75) MRTINNYEYTSFTEDLEETDYTHPHVVRRDPEVTYEDTFAKKELLSRYPALYENLIRGW SRSYYTGQEHLRAIMQYATPNTNFSECVQHAYTKAITKVTESLHSLPTVRAFNVLEELD LIPYESSSSAGYTYRGVKGPQHGENHMQAIKTAKAVLWSVIKDDGEGIEHVIDTYVPDV GYTRTQLTDLREKMKVRGVWGRAFHYILLEGTSAAPLLEAFANSNTFFHIGKDPTVSVP YLISYTKGQAPWLTAIDWQAFDATVSRFEINAAFDIIKSKITFPNLETEQAFEISRQLFIHK KLAAPNGKIYRIHKGIPSGSYFTSIIGSVVNRLRIEYLWNLKFNRGPKVCFTQGDDSLIGD DELYSPMDMAAFVKPLNWFINTSKSMTSKVPEAITFLGRSSLGGLNQRDLKRCLRLLILP EYPVTSGDISAFRANSIWRDSGSTSQILHEIANALRRKYGIAKEQDVPRYLRPWKA Botryosphaeriadothideapartitivirus1 (SEQIDNO:76) MLLTEIPNVYQRALALERRIRVRELFPEGLVPYLKRQEHAGSIASPIGPSRSVAPKVTDKF IAKAPLEDYPDKRYTLECTSTMQYIGQMDAYPFHSSIPEFDPWFRHVLKARAPDVSLHL EQTYTRDPCTPDRVMSFLKLFDRTWKRKPTGRLMSQAESIVKKMFKCVGQVNPIDFNY AGWHEILPHLDMSSSPGLPLRREYATQGECLGHIYDKSKRLNHFAKFLHPAAVRAPPC MIGLRPGLLKKDELDEKIKARGVWAYPAEVKVIEMRYVIPLLERFKSQFGKIPYPVGVN LTKALPFIIDHLLNDGKHGFVTDVSKLDTSVGPDWIDWAFSFLKDFYYMGMTESSETRN SHVFDFLHYYFKRTPILFPSGQLVRKSGGVPSGSGFTQIVDTLCTLLMTTYSMLRMGYQ EDDIIGKIFAVGDDMATSVPSSFDVEQFSFYVGQLGFEINVDKVMFSNRGIELKFLGYSK YGGNIWRPIDELLQTAYFPEKYVGNPERSRQRILGQTLASGLTNGFLSKVNYWMEELCS WHTELDTDEVYIPQKRWMRNVLGLDEIPRSALLFDIFPLC Citrulluslanatuscrypticvirus (SEQIDNO:77) MNISPLLYEQCLSGWSRSYYLHDKHMQAIIQYGYKDVPISSINDRLYKECVHEVQNRLS SLPRVRALDVLSELDSVTFKSSSAAGYDYIGAKGPKGGENHTRAMSRAKAIMWSIAET GETGMKHAIETAVPDVGYTRTQLADITEKTKVRHVWGRAFHYILLEGLTADPLIRAVQ RADTFIHIGKDPTVSVPRLLSDTAEQCKWLYALDWKQFDATVSRFEIEAAFDIVLNLLDF PNRETKLMFELSKQLFIHKKIAAPDGKIYWAHKGIPSGSYFTSIIGSIINRTEILMLWRTIT GHGPIVCYTQGDDSLCGDNILIPPERFAMVANPIGWYFNQEKTEYSTIPELITFLGRSYAG GLNKRDLKRCLRLLIFPEYPVESGRISAYRAQSISDDVGGLGDVLNKLADRLRRSIP Diatomcolonyassociatedvirus14 (SEQIDNO:78) MQEMTYSGVRYRTSNQGDYITKHPFGLSQIGSHKFTPVRRDPHTTIIDPFMMEAFQDYG DRFNFAKLDGWSRSLYTREGHMDSIHRIQSHTRFHKPTDTSMTKTDDYCLQIFRTLGTV RSLDYHTQLGQVPFEPNSAAGIGIPGKKGDSGNLALAINQAVATLQRSLRDGISSVIEDS TPDMAYTRTQLTQLSAGIKVRNVFGQAFQYILLEGLSASPLMDHFVTNETFFFVGSDRPRI SVPTLLEDFKKKGSLMMSIDWSAFDTSVENWEIVDAFNLLETILEFPNLETRAAFEFSRIL FINRKIAAPDGNVYFKQKSVPSGSYYTMLIDSIINWRRILYLHHRATGFFPFDIRTQGDDS LVATRDSVSPEALMLQIPRNSQWQLNPSKCPIGKSGSSVPFLQRTLKWGDQSRDLDRVE RLAIYPEYEVESGDISAFRARALWEDCNYESVVLAHATSYLESKYGIPTTVPRRYTNIW QTLFESKEREGLR Fragariachiloensiscrypticvirus (SEQIDNO:79) MEHRFRGIPRGLIELEEIPTRRLREERVVHIDAWSSKAIDAIVPLSLRIELDGWARSYYTL QAHIDSIMQYDRPKLPQPTNAAWNTTTQHVRTQFARMDKVQTLSYLQLDQVKWVRSS AAGYGYVGRKSDNDNYFRARKTAFTIAEKLNHDRDYGPLALEDSTPDIAFTRTQLCQIK VKRKIRNVWGEAFHYVLLEGLFADPIIQHFIRNKSFYFIGEDPLLAVPRLVEKILSEQDYV YMFDWSGFDASVQEWEIRFAFSLLESILIFPSSVESYIWHFIIELFIYRKIAAPNGKVYLKT LGIPSGSCFTNIIGSIVNYVRIQYLFFRLTNNFVTVFTHGDDSLVGVSTTQYVQMDNFEPI CAEHNWTINIAKSAVSHEAGVSFLSRKVREHCHARDELLCLRMLKFPEYVVESGAMS TLRAHSIHQDAGINSRYLYSIYKYLLHRYGKADSLPLNQQNWDPLEYENLRVSFATQNY E Figcrypticvirus (SEQIDNO:80) MEAGLIEIGNIPERHLRDEFIILVDQPAYDSVRRNAPQADMQEIDGWARSFYTVEGIMAS IMQFSKPLIHEPTDPIWNDVKRETLMKIGSLFPQVQSLPFEGGFDHVPFESSSSAGYGYD GKKGEGNNFHRAKSIANAAVRKFSEDIDNQGYDYAVSHLIQQGPDIAFTRTQLAKLPS IKVRIVFGEAFHNILIEGLSAAPLLEAFKRMDTFYFTGKDPTIYVPRILHKMSTNEGWFIC LDWKAFDASVQLWEIDHAFNCIQQLLAFPTELSRLAFLFTRESFKQRKLADPNGILWMR KGGIPSGSYYTNIIGSVINYNRIEYVCKRLGLQKTSCYVQGDDSLIHITGDAKPDLTQLQ MLGEQFGWTLNIPKCSLTQDSQLVTFLGRSQMHQLNIRERLKVLRLMCFPEYKVEDPKI STTRVKAIARDAGWSDPVYNKIYLQLKRLYGEVERLPPHLATFVDRFDFQDVNM Flammulinavelutipesbrowningvirus (SEQIDNO:81) MSDTLIDSFSRLTLSVKNFVFLGFTETQNYPQKSDSAILSHRKVVLNAFEKYLNPIEYNH VANEYKRSETDLDSTKAAFFKGDIPDHEVPRDEHYNRAFSVIVSKFRPPEPIRPVHYADL RLYPWPLKPSAEAPFSNDKSLLALLALRNRQGFLPNAKPNFHNLFNWVFGFNRQCVHLI KKGKDNLGPNEYWPAHGFLYPINIHTKSAIIGIHDPNKVRTIFGVPKLTVMVEAMFFWP LFRYYRFEQQSPLLWGYETMLGGWYKLNHELHLNPFYQGSILSLDWSFFDGRALFSVIN DLYSDKGVKSYFEFNNGYIPTVDYPDSSTHPQKLHNLWDWMLTALKFAPCALADGTI WQRTVRGIASGQFTTQFMDSIYNGLMILTILSRMGFVIDETLPIKLLGDDSVTRLAVSIPA SMHESFLIEFQRLADYYFSHTINVKKSKISNTPHNVSVLSYANNNGLPVRSRTSLLCALL YPKSRRPTWEHLKARAIGVYYASCGIDRTVRLICKDIFDYLDSQGIQASSAGLQDLFDPN FKSGTIPLDVFPSVEQVTTNLRSFHHLDNSDKERYFPTSHFLDTK Heterobasidionpartitivirus12 (SEQIDNO:82) MQTLLSAVYSIRDAIFGKTLSEPHGLNVNFHFDGYVTDEIKTSIPPRVEMWYSDYQKFL NPIIRANFTGAEADKIINGYHHPVATIPFMVENLKKGDLSDHPVPHDEHYLRARKMAAD AFRPPRPIRPVHFADLRFYNWNWHPNVEEPYYSNKRAQEYVQAAHTLGLTPDARMSFG NLRDYVFMDTRHYLHQIKRNEISNPKTLWPLMKIHVKPALTGTDEQKIRVIYGVSKRHV LPQCMFFWPLFRHYIENDTDPLLWGFETILGGMMKLNSLMHRLYFQTFVTVDWSGFDL RSLFSIQREIFDDWRTYFDFSNGYIPTVWYPNSTADPIQLERLWNWQRDACFNMPFVMP DKSVYRRLFRAIPSGLFVTQFLDSHYNYIMLLTILSAMGFDITIERIRILVQGDDSLKNLIF FIPANQHDNFKAEFQRLATYYFDHVARPEKTEIYNSPQGVTVLGYTNNNGFPTRDPIKL MAQLYHPRQVGERWKSVLMAKCAGFAYASAYNYPKVTATLKTVYYKLAAKGFSPAA LRTQRDIVLFGEAKFQVPTDHFPTAEEVQRHLRVPYKRTEEDSESYFPMKHFLDFA Heterobasidionpartitivirus13 (SEQIDNO:83) MLPIISQVTDYVYRKFIKPAPTQFKNNYLFQNWLSPLTTPHRDATKYAEYQAYLEKHIR SNLLGSDAEYVIKRFHHPIATIDSVNETLQRGDLPDHPVPKDEHYYRALTETTKRFAPPQ LIRPIHFADLRYYEWNWHPNVEEPYVSNSQLKTAVQDAYHAGLLEDGRMSFGNLKNH VFMDVRHFLHRIKRGQISDPHTLWPLINMHWKPALTETDTTKIRLVFGVSKRHVLPRAM FFWPLFRYYLDNRDKSPMLWGFETILGGMMLLNSEMLLSRLYYQTFVTVDWSGFDLRS LFSIIREDIFPAWRTYFDFNNGYMPTKFYKSSTADPDQLERLWNWTNEAVFKMPFRTM DGATFLRLFRGIPSGLFETQFLDSFYNMLMILTILDAMGFDISTIYIRVQGDDSLLLLTFFL PADQHAEFKAQFEALAAYYFDHVARQDKTDISNTSQNVAVLGYSNDNGYPSRDWRKL LAQLFHPRSQRPTLSLLKARCCGIQYASMYKYPQVTNVAKATFNQLDSEGVQPVKLAA QRDVILHSHKDFYVPTDHFPTLNEVTRYLRIPYTRTEADSETYYPMSHFLSQF HeterobasidionRNAvirus3 (SEQIDNO:84) MKIFSTLYSSFASFAKWTGLTDPHGFEHNFYFTGYADKKIKVSINPRFQEVYDDYQSYV GKFIDKHLPGHMAQKIKFGYHHPVASLPFMITNLKKGDLPDHPVPHDQHYTAARKAAA DAFRPPRLVRPVHFADLRYYKWNWHPNVEEPYYSDPKLQQYVEHCYALGLIDDARLSF GNLKDFVFMDTRHYLHLIKNGSITDNNQLWPIMKIHVKPALTEPTETKIRVIYGVSKRHI LAQAMFFWPLFRYYIEEHTSPLLWGNETFTGGMLKIHNLISVPRLYSQTYLTVDWSGFD LRSLFTIQREIFDDWRTYFDFTAYIPTRTYPDSKTDPIRMERLWNWQRDACFKMPFVLP DRTTYARLFRSIPSGLFVTQFLDSHYNLIMIYTILSAMGFDITNLMILVQGDDSLIHLKFFL PADQHDAFKAEFERLAKYYFDHIARPEKTHVTNSPNEVEVLGYTNNNGYPSRDMTKLV AQLYHPRNVDKTSWKSLLMAKVCGFAYASCYQDSQVIDLLRSIYNNLASKGFKPKSGR VMRDIILFGESEFEVPTDHFPTLNDVTKYFRRPYVRTQRDADSYFPSWHFNDVF Peppercrypticvirus1 (SEQIDNO:85) MVRGTLVGYDYTQFQGDLVKSTHRHPHVVHREIATTYVDQYAYEHIETFSSLYPELILK GWSRSYYLPEKHLAAVLNYSMPNVPASQLSQSLYRQAIESAKNGFISLPRVKAFDVLTE MDQVPFKSSSSAGYNYTGRKGLIGDENHSRAISIAKAVLWSAIKDDGEGIEHVIRTSVPD VGYTRTQLTDLLEKTKVRQVWGRAFHYILLEGLVAYPFIQTVMSHKTFIHAGQDPLISV PRLLSDVALNCKWIYSLDWSQFDATVSRFEIHAAFDIIKSYVDFPNYETEQAFEITRQLFI HKKVAVPDGYIYESHKGIPSGSYYTSLVGSIINYLRINYLWRLLTGHPPQQCHTLGDDSL VGDNSYVNPQAIEEAANKLGWHFNPDKTQYSTVPEEITFLGRTYVGGLNKRDLTKCIRL LVYPEYPVESGRISAYRAKSIAQDAGGLSEVLNRIADKLRRIYGTASEEEVPIYFKRYVF GV Peppercrypticvirus2 (SEQIDNO:86) MAIYRMLNGYVFTAFGNDLEKLDQRHIHHIRREEATTYRDEFALKELMDLSPILYEQFL EGWSRSYYEGSKHLQAIIQYGIPDPDPGLIDNDIYNKAGYVVLESLGSLPRVRAFDVLTE LDSVHYEQSSSAGYDYHGPKGPIQGENHIRAITRAKATLWSAIKDEGEGIEHVIRSAVPD VGYTRTQLTDLYEKTKIRGVWGRAFHYILLEGTIANPLLDVFKRGGTFYHIGENPQYSV PDILSQVSECCKYLVAIDWSNFDATVARFEINMAFDLIKTLIMFPNIETELCFEICRQLFIH KKIAAPDGNIYWSRKGIPSGSYFTSIIGSIVNRLRVEYIFRKAYDVGPKMCYTQGDDSLIG VDFRVDPDRLSEIAAPLNWKLNPAKTDVSLYPEHVTFLGRTMYGGINQRDLKRCLRLLI FPEFPVPSGEISAYRAVSIAQDAGGTSEILNSIAKRLRRQYGVAEEHAVPKHFKLYIP Persimmoncrypticvirus (SEQIDNO:87) MALRSITGYEFHDFQSSLELLNQTHIHIVRRESGVTYHDEFALCELLVDNTRLYEQELEG WSRSYYTGEQHMKAILQYSLPNTPIQDIDVGCYQQAMTNVQERLSSLPIVRAFDVLTQL DQVSFESSSAAGYDYTGAKGPKNEGNHERAIRRAKAVLWSAIAQDGEGIEHVLRSSVP DVGYTRTQLTDLSEKTKVRGVWGRAFHYILPEGTSADPLLQAFKEGGTFYHIGQDPTVS VPYILSDTAGKCAWLYALDWSSFDATVSRFEIHAAFDLLKQRIEFPNFETEQCYEICRQL FIHKKIAAPDGKVYWAHKGIPSGSYYTSIIGSIINRLRIEYIWIKLRGHGPTICYTQGDDSL CGDDERIEPERIADIANPIGWLINPAKTATTRYPEYITFLGRTCYGGLNHRDLIRCLRLLIY PEYPVPSGAISAYRANSIAEDCGGTSSILNDIARRLTRKYGRVSHEEVPKELRVYRH Rosecrypticvirus1 (SEQIDNO:88) MEHRFRGIPRGLIELEEIPTRRLREECVIHIDAWSSQAIDAIVPLSLRNELDGWARSYYTL QAHVDSLMQYDRPKLQPPTNTAWNITTQYIRTEFARMKKVTALSYLQLDQVKWVRSS AAGYGYTGRKSDGDNYIRARKTAFTLAEKLNHNRDYGPLALEDSTPDVAFTRTQLCQI KVKRKIRNVWGEAFHYVLLEGLFADPLIQQFMRIKSFYFIGEDPLLAVPRLIEEILSEQDY IYMFDWSGFDASVQEWELRFAFGLLESILIFPSSVEHQVWQFIIELFIYRKIAAPNGKIYL KTLGIPSGSCFTNIIGSIVNYVRIQYMFFRLTREFVTAFTHGDDSLVGVPTTQYVQMENF KPICDENLWTINIAKSAISREAEGVSFLSRKVREMCHARDELICLRMLKFPEYIVETGAM STLRAFSIHKDAGIHSRYLYQIYKFLLHRYGKADSLPLNQQNWDPIEYENLRVSYATQN YE Rosamultifloracrypticvirus (SEQIDNO:89) MEHRFRGIPRGLIELEEIPTRRLREECVIHIDAWSSQAIDAIVPLSLRNELDGWARSYYTL QAHVDSLMQYDRPKLQPPTNTAWNITTQYIRTEFARMKKVTALSYLQLDQVKWVRSS AAGYGYTGRKSDGDNYIRARKTAFTLAEKLNHNRDYGPLALEDSTPDVAFTRTQLCQI KVKRKIRNVWGEAFHYVLLEGLFADPLIQQFMRIKSFYFIGEDPLLAVPRLIEEILSEQDY IYMFDWSGFDASVQEWELRFAFGLLESILIFPSSVEHQVWQFIIELFIYRKIAAPNGKIYL KTLGIPSGSCFTNIIGSIVNYVRIQYMFFRLTREFVTAFTHGDDSLVGVPTTQYVQMENF KPICDENLWTINIAKSAISREAEGVSFLSRKVREMCHARDELICLRMLKFPEYIVETGAM STLRAFSIHKDAGINSRYLYQIYKFLLHRYGKADSLPLNQQNWDPIEYENLRVSYATQN YE Raphanussativuscrypticvirus1 (SEQIDNO:90) MSNLEYLGLDHHWPAIPRFAKSPNDWYFACQQLVRSSICLYSSLLGSNDTDTVLNGYY RSHADEDTAEQFFMRYDVEPFDIIKDNYYSQAFDTVTEWFRPSAPIHPVHFTDVRWYP WKISTSAERPFTHDPLLKKKVQLSKQLGLLDNARMSFHNCYNDIFTYCRHYTHEVKDA RPVTLHHIDLHVKPALVRSGEPPKIRTVFGVPKSLIFAEAMFFWPLFSDYFTNSETPLLW NYETLNGGWYRLNDEFYQQWQSFCTIFNLDWSEFDMRVYFSMLDDCRDAVKSYFCFC GNYCPTRTYPTCRTNPQRLQNLWNWIGTAYKDTPCTTTTGKVYRRRFAGMPSGIFCTQ FWDSFYNCIMVVTTLEALGFRITDRYFLKVLGDDVIFGILKHIPISKWADFLQDFSTEAR RRFNSKLNSKKCGASSGIHGAQVLSYINWNGYPKRDSNQLLAQLLHPKSLRDTYPRLM ARAIGIYYASCGDPKIRPICNHIYSELKYAGFTPSSTGLHGLFDPNASIGFIELDHFPSENE VTCRLHRKSKRSAELQALYWPRDHFLEEAGSSRNCPLSFQVETI Raphanussativuscrypticvirus2 (SEQIDNO:91) MDHEFRKIREGLIEIGTVSLRVQRDEFKVIIDEYAAEAVFKFVPSTMLSQLQGWARSVYS LDQHVDAILAYRRQKLPEPTDDVWNQTKQHTLQLFRRFPKITPISYKSFDEVKWISSSSA GYGYVGHKGDGDNYLKARRTAVTIAEKLDHDRNYAPEAINQSTPDVAFTRTQLSQVK VKTKVRNVWGEEAFHYVLLEGLFADPLINFFSNEESFYFIGRNPLLSVPTLIEEIFKSKDYV YAFDWSGFDASVQEWEIRFAFQCLESQLIFPSNVEAQIWRFIVELFIYRKIAAPNGTLFLK TLGIPSGSCFTNMIGSVVNYVRIQYMFKKLTDDFVEAYTHGDDSLAAVSTAQYIPLEKF GPICEPFMWSINTLKSEVSREGRLTTFLSRSIRDKQNYRDEFVCLRMLVYPEYEVEDGSIS ALRAKSIYVDAGIHSQYLYHVFLYLKQKYGLANTLPHNLRTWDPTEHEALRASYSNIM RhizoctoniasolanidsRNAvirus3 (SEQIDNO:92) MVDALRKGDLPDHVIPKDEHYSKAFAQAAEMFRPPQLVRPVHFADLRMYKWNWHPN VEEPFYSDADLIRAVSMAAEAGLLPDARMSFGNLRNVVFIKARLFLHQIKRKQITNPAT LWPMMKIHVKPALTKVDETKVRIIYGVSKLHVMAQAMFLWPLFNYYINSDDDPLLWG FETILGGMQKLHNIMSIPRLYFQTFVTVDWSGFDLRSVFSLQREVFDVWRTYFDFNNGY IPTKFYRTSVADPDHLEALWEWQREACFKMPFVMPDRTMYNRLFRCIPSGLFSTQFLDS HVNLVMILTILDAMHFDISKIKIYVQGDDSIVMLIFHIPADQHIKFKSDFEVLAKYYFDHV ARPEKTDVYETPQGVEVLGYRNYNGYPERDWRKLLAQLLHPRGALSLETLAARCCGIA YASMYRNPEVINVCKDIYNYLTTKRNVVPGELRAQRDIILFGEHEFSIPTDHFPERDEVT RHLRIPYVRTDSDKNDYWPSGHFLSLY Sinapisalbacrypticvirus1 (SEQIDNO:93) MRPSITGYDYTNFTQDLLKSDRKHPHVVRRETATTYRDDFAFKEVISLDRLAYIQRLEG WSRSYYLPEKHLEALLQYATPNVPCTALNLNVYRQAIQVVENGLRSLQPVRAFDVLTE LNQISYKQSSAAGYDYIGAKGPIDGENHKRAISRAKAVLWSVVKEDGEGIDHAIETSVP DVGYTRTQLADLTEKTKVRQVWGRAFHYILLEGLVAQPFIQSIMEGPSFIHTGRDPTLSV PQSLAKVSSQCKYIYSLDWKSFDATVNRFEINTSFDIIKSKVIFPNYETEQAFEITRQLFLH KKVAAPDGYIYEAHKGIPSGSYYTSMVGSIVNRLRIEYIWRIATGHGPIHCETLGDDSLC GDDIFVPATQLADIANRIGWYFNADKTEYSTIPEGVTFLGRTSTGNLNSRDLTKCLRLLV YPEYPVTSGRISAYRARSIADDSGGLSDLLNQVAIRLERSYGIASEEEIPAYFKRYVPFM
The Following Representative Amino Acid Sequences are of for RdRp's from Group IV Partitiviruses (genus Gammapartitivirus):

TABLE-US-00008 Aspergillusfumigatuspartitivirus1 (SEQIDNO:94) MEDYTQDPTQHYVLAKGSHLIDALQLRPARSGKSSTTSYDVLPSNFESDTLREIARYGG YSTYSSASNTDPWVRESLKIFDRDQYEAIRGFTRRPQGTPGMYESLKKFSTEERSTFWSL SPQQRTSMRRAIGKAKRAFKLPYKREPLDWHEVGQFLRRDTSAGATFMGQKKGDVME QIYHEARWLGHRMKQDGIGPFQPHKMRFPPCLAGQRGGMSERDDPKTRLVWIYPAEM LVVEGFYAPLMYRDFMNDPNTPMLNGKSAQRLYTEWTCNLREGETLYGIDFSAFDAR VPAWLIKAAFAILRQNVDFSTFRGKPVNKRDAQKWRNVWDAMVWYFINTPILMPDGR MFRKFRGVPSGSWWTQMIYSVVNYIMIEYLADCQRVEIRNLRVLGDDSAFRSGDQFDL DVAKGDAEPTQMLVNTDKSGKSKDPADFKLLGTTYRCGRVHRPTDEWFKLALYPESS VFSLGLSFTRLIGLWLGGAMHDATFSRFIEFFQQCYPCPEEGWFSKDQRRWLEIVYSGK APRGWTTKKSLFWRSIFYAYG AspergillusochraceousvirusFA0611 (SEQIDNO:95) MDDSHLDPTQLENVIEESLLLDDSTLTPSAKVRGASYNVIPPQFSSPGLSEIARYGGYGT YSGQSNTDPWVRVALKNFDRNVYDDVYGFTRKPEGTPGMYKSLFKFAEGRSDFRSLN RAQRKAMQAAISKTKKRFKLPYKSDPLDWHAIGQFLRRDTAAGATFMGCKKGEVMED IYHEARWLAHRMKQDGRQRFNPKQMRFPPCLAGQRGGMSEASDPKTRLVWIYPAEML VIEGQYAPTMYHKFMADPHTPMLNGRSSTRLYTDWINDAKEGDKLYGLDFSSFDSKVP SWLIRVAFNILRQNINFETWNGQPVSKRDRQKWRNVWDAMVYYFINTPILMPDGRMFR KYRGVPSGSWWTQMVDSVVNDILVQYICLCQEIEPRDLRVLGDDSAFRSCAELVLVQA ERDAKDVNMVLHPEKCDVKTDPTKMKLLGTTYRNGRAHRDTDEWFKLVLYPESSVRT IEVSFSRLIGLWIGGAMFDSAFCRFMEYYQTCFQCPEDGWFSKEQRRWLEVVYGNRAP RGWSAKKSLFWRSIFYAYA Botryotiniafuckelianapartitivirus1 (SEQIDNO:96) MEEFTQEPTQHYVLAKGSHLIDALHLRPDTGKGSTTSEDVLSSDYRSPNLAEIARYGGY STYSSNSNTDPYVRETLKLFSRDTYEDIRGFTRRPEGTPGMYKALEKFSGEKNSFNDLSA TQKSSMRRAIGKAKKAFKLPYKREPLDWHEVGQFLRRDTSAGSTFMGQKKGDVMEEI YHEARWLGHRMKQDGKGRFNPTKMRFPPCLAGQRGGMSERDDPKTRLVWIYPAEML TVEGFYAPLMYRDFMNDPNSPMLNGKSAQRLYTEWCCKLREGETLYGIDFSSFDTKVP AWLIRIAFDILRQNIEFSTFQGKPVSKKDAQKWRNVWDGMVWYFINTPILMPDGRMFR KFRGVPSGSWWTQMIDSVVNHILIDYLADCQDVEIRNLKVLGDDSAFRSSDEFQLETAK LDCKPTGMVIKPEKCEKTADPADFKLLGTKYRSGHVHRDTDEWFKLALYPESSVFTLD VAFTRLIGLWLGGAMWDKRFCEYMDFFQSSYPCPEEGWFSKDQKRWLEVIYSGKAPR GWTTKKSLFWRSIFYAYG Colletotrichumtruncatumpartitivirus1 (SEQIDNO:97) MEDFTQDPTQHYVLAKGSHLIDALHLRPAKPGSTTSEDVLSSDFESPNLREIAKYGGYST YSSNSNTDPWIRETLKIHDRETYEQIWGYTRRPQGTPGMYTALGKFAGEKNVFGDLSSS QQSSMRRAIGKAKKAFKLPYKREPLDWHEVGQFLRRDTSAGSTFMGQKKGDVMEEIY HEARWLGHRMKQDGKRSFDPTRMRFPPCLAGQRGGMSERDDPKTRLVWIYPAEMLV VEGFYAPLMYRDFMNDRNSPMLNGKSAQRLYTEWCCNLREGETLYGIDFSAFDTKVP AWLIRAAFSILRQNVNFETFQGKPVEKEEAQKWRNVWDAMVWYFINTPILMPDGRMF RKFRGVPSGSWWTQMIDSVVNYILIEYLADCQKVEIRNLRVLGDDSAFRSGDQFSLESA KIDCIPTGMIIKPEKCERTKDPSDFKLLGTKYHDLHPFRDTEEWFKLALYPESSVHTLDIS FTRLIGLWLGGAMWDRKFCEFMDFFQTSYPCPEEGWFSKDQKRWLEVIYSGKAPRGW TTKKSLFWRSIFYTYG Disculadestructivavirus1 (SEQIDNO:98) MEEFTQDPTLHNVQAEESHSIDTLHLRDAKRGSSTSEDVLHKGYADPCLREVAKYGGY STYSSNSNTDPWIRETLKIHDRETYEDIWGKTRRPEGTPGMYKALGRFGGEKCDFDNLS DPQKSSMRRAIAKAKKAFKLPYKREPLDWHEVGGFLRRDTSAGSTFMGTKKGDVMEEI YHEARWLGHVMKQDGRKGFDPTKMRFPPCLAGQRGGMSDRTDPKTRLVWIYPAEML VVEGFYAPLMYHDYMNDPKSPMLNGKSAQRLYTEWCCGLRDGETLYGIDFSAFDSKV PAWLIRVAFDIVKQNINFETFEGKPVDKHDAQKWSNVWEAMVWYFINTPILMPDGRMF RKYRGVPSGSWWTQIIDSVVNNILIDYLADCQQLEIRNLKVLGDDSAFRSTDQFDLEVA KDDCVPTGMVIKPEKCERTEDPNDFKLLGTKYRDGRVYRSTDEWFTLALYPESSVLTL DVSFTRLVGLWLGGAMWDKQFCAFMDYYQTSYPVPEEGWFSKDQKRWLEVVYSGK APRGWTTKRSLFWRSIFYAFG Disculadestructivavirus2 (SEQIDNO:99) MEGFTQEPTNTTVLAEELHSVDTLHLRPGKTRSTTSEDVLPNNYEDPCLREIAKYGGYS TYSSNSNTDPWIRETLKLHDRQIYEDIWGKTRRPEGTPGMYKALGRFGGERCGFDDLSS QQKSSMRRAIAKAKKAFKLPYKREPLDWHEVGQFLRRDTSAGSTFMGSKKGDVMEEI YSEARWLGHRMKQDGRSRFDPTKMRFPPCLAGQRGGMSDRDDPKTRLIWIYPAEMLC VEGFYAPLMYRDYMSDPNSPMLNGKSSQRLYTEWCCNLREGETLYGIDFSAFDSKVPA WLIRTAFDIVKQNINFETFEGKPVNKVDAQKWKNVWDAMVWYFINTPILMPDGRMFR KYRGVPSGSWWTQIIDSVVNNILIDYLADCQSVKIPKPEVLGDDSAFRSNDQFDLEVAK DDCVPTGMVIRPEKCEKTEDPAEFKLLGTKYRSGRVHRSTDEWFSLALYPESSVLSLDV SFTRLVGLWLGGAMWDKQFCEFMDYYQTSYPVPEEGWFSKDQKRWLEIIYSGKAPRG WTTKKSLFWRSIFYAYG GremmeniellaabietinaRNAvirusMS1 (SEQIDNO:100) MSEVDNTDPTLQDVAFVKSSGLDTTHLRSSEKTAGASYSVISSNFNSPGLTEIARYGGYS VYSGNQNTDPWVRATLKNFSRETYEQIYGFTRQPEGVKGMYSSLLKFSDGKCKFDRLN RVQRKAMIGAIAKAKKAFRLPYKSEPLDWHQVGAHFRRDTAAGVSFMGKKKGEVME EIYHEARWLGHRLKQNGKARFDPRQMRFPPALAGQRGGMSKRDAPKTRLVWVYPAE MLVVEGQYAPVMYRAFMDQPDTPMLTGASSQRLYTEWLVGRREGETLHGLDFSSFDT KVPSWLIRVAFDILRQNIEWETWQGEKVSKRDRQKWRNVWDGMVWYFINTPILMPDG RMFRKRRGVPSGSWWTQMVDSVVNYILVEYLTECQGVEARGLRVLGDDSAFRSPVEF SLEQAQSDCEPTGMILKPEKCEKTEDPSDFKLLGTTYRGCHPHRDTNEWFKLALYPESR VGNLEVSLSRLVGLWIGGAMWDKEFCSYMDYFQSSYPCPTEGWFSKDQRRWLSIVYG GKAPRGWGDKKSLFWRSIFYTF Magnaportheoryzaepartitivirus1 (SEQIDNO:101) MEKTSPDLPFTKDVLTSADWDAVHRSLSYGNPGLTKIPADKWCYKYNVEQTRMNTDP FVRKAMKLWDETEYKQLYGYTKKASLEHGLNGLNKYGRPQRQKSHMPSEFKGSYHR ALQEATRVFTPHEPLHRLSVPDVWDNMNLDSAAGFTFPGKKKSEVVEEAFDTASYMA HFISAGKHIYVPPAKLALRGHLSELEEIKTRPVWVFPFEVTILEGKWAIPYYRFLEEEVPS VHFGEGAMQRLAKILDSDIASHAEYAELTMDWSGFDTGVPNWMTDDALDILFGAFDE TAVQHQDDLVVGGEYMAYKNEAVKDFLKTYFKKTKILLPDGSVYKKNHGIPSGSFFTQ AIGSIINYIAVRTLDFYFGWNGRRFKVLGDDSSYLIPNGLGKVSVDAVSKAAWAAFGFT LKREKLRIATKQHERKFLGYQVSAYRYERPSDDWLKMALYPERDCEFLEQSASRVFAF YLLGGCNDATYCDFFHDYLNRYPVVYGSELFPLTKGLKRLFKFVLRLNVERLVFLDLPN FDPLKGPFALSLGDKPFG MycovirusFusoV (SEQIDNO:102) MVELFVMVDPTTKRRRIQSTLGPFLSVPGLQEIARYGGYATYRAVRNTDPWIRQSLKLF DPDLYGNIYGFTRRPAGPEGMYKSLMKFGESMPRFTDMSTVQRSAMKTAITAARKRFK TPVKFEPLEWSEVGQHMRRDTSAGVSFPGKKKGDVMERIYAEGRWLGHRMKQGGKG RFDPRKVRMPPCLATQRGHLSPRDDPKTRLAWIYPSEMLMVEGLYAPTMYKAFEAMP DSPLLLGKGSHRLFSEWVSAATPGMRLYGLDFSSGDTKVPAWLIHTAFDILHDNIDWLH WRGKPTTKRSRQKWKNVWDGMVYYFINTPILMPDGRMFRKRRGVPSGSWWTQLVDS VVNWILVKYLSLCQGVNAKNLRVLGDDSAFMAAETMDLSVAAEDAAAVGMDLSDEK SISVEDATELKLLGVRYRDGHAFRETEEWFKLALYPEGDVPDIATSLTRLVGLWIGGAM WDTKFSRFMEYFQGCYPCPSEGWFSKDQRRWMEIVHGGRAPRGWTKNKNLFWRSIFY TL Penicilliumaurantiogriseumpartitivirus1 (SEQIDNO:103) MAFTQEPTQHYVLAKGSHLIDSLHLRPAKAGSATSEDVLPTGYNSPNLREIAKFGGYST YSSASNTDPWVRETLKLFSRERYEEIYGFTRRPEGTPGMYKSLAKFAGEKSHFRDLTVS QQKAMRRSIAKAKKAFKLPYKREPLDWHEVGQFLRDTSAGSTFMGQKKGDVMEDIY HEARWLGHRMKQDGESSFNPTKMRFPPCLLAGQRGGMSERDDPKTRLVWIYPAEMLVI EGFYAPLMYRDFMNDPNSPMLNGKSAPRLYAEWCCGLREGETLYGLDFSAFDTKVPT WLIYTAFDILRQNIEWSTFQGKPVSKQDAQKWRNVWDGMVWYFVNTPILMPDGRMFR KYRGVPSGSWWTQMIDSVVNYILIDYLAECQEVEIRNLRVLGDDSAFRSTDQFSLEQAK VDCEPTHMLLKPEKCEKTKDPCEFKLLGYYTRDGRVHRPTEEWFKLVIYPESSVHTLDI SFTRLIGLWLGGAMWDKEFCRYMDFFQSSYPCPEEGWFSKDQKRWLEVIYSGKAPRG WTTKRSLFWRSIFYAYG Pseudogymnoascusdestructanspartitivirus-pa (SEQIDNO:2) MEVSPFDPTPLDNVIEGSPLVDDSLLVPSSRTRGSSYDVIPEHFNSPGLTEIARYGGYPVY SGGSNTDAWVRTSLKEFDRTMYENIYGYTRKPEGPQGMYKSLLKFSEDKSTFHSLNRV QRRAMIGAIKKARTAFKLPWKREPLDWHEVGQFLRRDTAAGATFMGKKKGDVMEEIY HEARWLGHRMKQDGREKFNPKKMRFPPCLAGQRGHMSERDTPKTRLVWVYPAEMLC VEGFYAPQMYRDFMNDRHTPMLNGKSSQRLYTEWCVGLREGEKLYGLDFSSFDSKVP SWLIRVAFDILRQNIEWSTFRGEKVSKREAQKWRNVWDAMVYYFINTPMLMPDGRMF RKRRGVPSGSWWTQMIDSVVNYILVDYLTQCQTCQIRGLRVLGDDSAFRSCHDFSLDQ ASADAAAVLMILNPDKCEVTLDPTKFKLLGTTYEDGHPHRETIDWFKFALYPESSVSSID VSLTRLVGLWLGGGMWDLHFCKFMDYFQTCFPCPLEGWFSKDQRRWLEVIFSGKAPR GWTTKKSLFWHSIFYTYC PenicilliumstoloniferumvirusF (SEQIDNO:105) METTTPDLPFDLHTREAYDYATFHRTLLHKPGLSRIKEDRWVYKYNVEQTRMNTDPFV RKSMKLWDEHAYHDMYGFTKKARLSNGLDAFQGFAKPQKQRSSMSPEMASCYEKAL EEARHVFTPHERLTRLSVPNVCDSTNLDSAAGFSFPGKKKSEVVEEAFDVASYIAHFVA SDRKVFIPPAKLALRGHLSEIDELKTRAVWVFPFEISILEGKWALPYYKFLEQNVPEVHF GEGAMQRLAKTLMTDVASHSECTEVTLDWSGFDTSVSNWLIDDAFDIMFDSFDETQVE HDGNFVLGGDHMAKKNEKVKKFLKTYFKKTKIMLPDGSLYKKFHGIPSGSFFTQIIGSI VNYLAVKTLDNYFSWNARRFRVLGDDSSFLIPFGRSKVDGVEISEKAWETFGFTLKLKK LRIANKQQDRKFLGYQCNAFRYERSTTEWLSMVLYPERDVEFLEQSASRVFAFYLLGG CNDVTYCEFFHDYLGRYPYIYGKELPLTRGLKRLFKFVFRLTIDKLAFPDLSRFDPLKVP FSLSLGDKPFW Ustilaginoideavirenspartitivirus (SEQIDNO:106) MEDFTQDPTHHYVLGKGSRLIDALHLRPAKEGQANSEEIVPSNFKSDTLREIAKYGGYS TYSSNSNTDPHVREALKLFSRDIYEDIRGFTRRPQGTPGMYGALAKFSGERNAFSDLSAS QQASMRRAFSKAKRAFKLPYKREPLDWHEVGQFLRRDTSAGVTFMGAKKGDVMEEIY HEARWLGHRMKQDGRDSFDPTRIRFPPCLAGQRGGMSEIDDPKTRLVWIYPAEMLVVE GFYAPLMYRDFMSDPNSPMLNGKSAQRLYTEWCCNLREGETLYGLDFSAFDTKVPAW LIRVAFDILRQNIEFSTFQGKPVNKEDAQKWRNVWDAMVWYFINTPILMPDGRMFRKF RGVPSGSWWIQMIDSVVNHILIDYLADCQDVEIRNLRVLGDDSAFRSSNQFDLEVAKQD CVPTGMVIKPEKCERSEDPSDFKLLGTKYRGGHVFRPTEEWFKLVLYPESSVLSLDMSF TRLIGLWIGGAMWDRKFCEFMDFYQSAYPVPEEGWFSKDQKRWLEVVFSGRAPRGWT TKKSLFWRSIFYAFG Verticilliumalbo-atrumpartitivirus-1 (SEQIDNO:107) MSDDIEIFDLLASPGEQPGSDETFASYGTPSSRTARRHVQAGEYFIGTGLEEIARYGGYSS HRASGNTDPWVRETLKLYDPERYESIYGFTRTGEGLLGAYKSLFKFDGPVARGTRLSTR QRSAMKKAIADARTAFKLPVKHEPLDWHEVGQFVNQSTSAGVSFPGKKKSEVMEEIYT AARWLGHRMKEGGKESFNPTKVRFPPALAGTRGHMSPKDDPKTRLVWVYPAEMLVV EGLWAPVMYRQYQSLSDGPLLLGKSAQRIYTEWCVNKKQGEVLHGLDFSGFDNGVPP WIIHVAFDILHANVDWLNWRGKPTSKRSRQKWRNVWDGMKWYFINTPILMPDGRMF RKHRGVPSGSWFTQLVDSVVNYILVKYAFNCQELKIHGLKVLGDDSAARSPLKLDLVQ AAVDFRPVQMRLNLDKCEITEDATEFKLLGTRYQDGHSTRPDEDWFKMALYPENPPPD IAVSMTRLVGLWLGGAMWSADFCKFFEYFQSSYPCPSEGHFSKDQRRWLEIVFGGSAP RGWTYKESLFWRSIFYVF Verticilliumdahliaepartitivirus1 (SEQIDNO:108) MEDFTQDPTTHNIVAEGSHLIDALHLRPPKLRSTTSEDVVPSKFRSPNPIDHDAMRGYST YSSNSNTDPYVRETLKLFSRDTYEDIRGFTRRPQGTPGMYTALKKFSGERNTFGDLSPSQ QSSMRRAIGKAKKAFKLPYKREPLDWHEVGQFLRRDTAAGATFMGQKKGDVMEEIYH EARWLGHRMKQDGRAGFDPTQMRFPPCLAGQRGGMSEIDDPKTRLVWIYPAEMLVVE GFYAPLMYRDFMSDPNSPMLNGKSAQRLYTEWCCKLRDGETLYGIDFSAFDTKVPAW LIRVAFDILRQNVNFETFGGKPVEKRDAQKWRNVWDAMVWYFINTPILMPDGRMFRK FRGVPSGSWWTQMIDSVVNHILIDYLADCQRVEIRNLRVLGDDSAFCSGGQFDLELAK GDCENTGMVIKPEKCERTKDPGEFKLLGTTYRGGHVFRDTEEWFKLALYPESSVLTLDI SFTRLIGLWLGGAMWDKKFCEYMDFFQSSYPCPEEGWFSKDQKRWLEIIYSGKAARG WTSKKSLFWRSIFYAYG
The Following Representative Amino Acid Sequences are from RdRps from Group V Partitiviruses (Unclassified Members of the family Partitiviridae)

TABLE-US-00009 Fusariumpoaepartitivirus2 (SEQIDNO:109) MHSLFTIVNLLLLARFQLRRKRKETTKTLIYPIRNILFEWELRRSTPR EPGIPLRYFDYSKSLLSYIDLQTCHKINIHLDDHTDALMERYASRDEP FAVYQHISDEDLPPERTPAPGIRHAQCRYHEIPSGTLNLDEKQHVLTD DPDFIETPEFRSGILYDETIDLSGSPPIPEIAQIIHDWFPHFEPFLAE YCRPPSFGPQAFRDFNRPTPHPPPPPHERHEAIMDIVRAKFNLKPYRP MHYVDALAAETPLNTSASYYSKFNPTSRVFARYSAPSRYKDKPTSKGY NFNVVMNEFRTEYHHIKYDGVPFPADLHDPEANASILNTWFAKHPSQL FIRTQISKRDPNDPKKIRPVYSVDDRFLHIEKTLVVPALAQLRNPQCC VAHGLETFRGSMSLLDRTALVYTSYISLDWSQFDQRLPYYVIIAFFLD FLPSLLIISHGYFPSRGYESTPQDIHAFASKIFNVVLFLTTWYLNMTF VSFDGFAYIREHGGVPSGLLNTQFLDSFGNMYIIVDCLLEFGFTPAEC LDMLYCVLGDDNLIFARQNFDRICDFMIFLTKYADTRHGMVVSILKSV YTKLRSKISFLSYENTYGMPTRPIGLKVAQLSMPERPIPDNRKWIHAA RALGLAYANCGQDAHFHLLCHMVYEKFRPDTPVPSLHIEKVFKKWKYQ LPEFDIESVTYTFPDFPTLFSIRQLVSDYHGFFSETDKWNTDMFEAPP SDNLHDYVTLKEYMNSNVHMSHTVNEFMHGKRSFL Heterobasidionpartitivirus2 (SEQIDNO:110) MSTNPPEVLLPLPEVDPNANNVRYAKLLDQYRANPSNSNQKLLLEYAE QHGFNYFIPTDVPLPDDRKSAPGILSLDGFRFHTVAAFHRYQKMSRYG YNALGFIFKLILTLFNPFLWILTDYCRPSGSADAVFENFNQEVSPVEH VNPSRLAQIMPLIHHFFAIKPFCPIAFPDLRFYKWSLVTSADYHAHHS KDQQDESAHYWKHLKDSDLLQDRFDYSDRPRSKGYFFNTVLLSTRTIV HNIKYHCLPFQRHKRDTDSSVLQKLSFWFMKYPTVMYVRSQISKLSKL KVRPVYNAPFLFILIEAMLTLALMAQCRLPDSCLMWGFETVRGGMQEL NRISYNYDTFIMIDWSRYDQLLPFAIIYHFWCTFLPQLIRVDLGYMPT EQYTATQHKHAFTEKHNDQKESNPEYATFASRLKTHAPHIVMFSFIIF NLLAFIWLWYVKMVFVTPDGFGYVRLLAGVPSGIFMTQICDSFCNAFL LIDAMLEFGFTPDDIKLIRMFIQGDDNVIFYLGDFTRIFAFYEWLPEY CQQRWHMTISVDKSSITRLRNKIEVLGYTNLNGMPHRDCAKLIATLAY PERYVQDKTKYIVFMSRAIGIAYANAGHDRQVHDLCQRAYLQARKDSG LSYDELKNIKIEYQKLGFYEIFSVNIEELREHLIQDVSEFPNFHDIRD NLRHWHGPHTVYPMWPRHFDDDLSSIKSPHSLTTLYDVMQSGGLTFDY NF Ustilaginoideavirenspartitivirus2 (SEQIDNO:111) MNSFENFGSFKLSADELAATAVPPTPWNNVFRYITDAKRFPGYKRGIL RQTQLYDPYVNAALKSFSPELHDSIKGYTRAPGDEWDVYERLTRYDKS PLAPVDNPRFKACYDAALSDVMKEFKLRDPVVPHWILDVDLVKNTSSG FPHFTRKGDILDQIRQEGRSHFHLLKRLPLWRVPLLPCTPATRGGLAD ITEPKTRLVWMYPAAMTAVEAVFAQPLIDGLFSEKSEYLITGVDTKHR IQRYLSLLSEDTGRLGVGLDFKSFDTLRCNWLIRDAFDVLKQNVYFSG YYDDTNGLQTFGPGKTERLEHAWSNIVEYFIHTPILLPNGRCVNKHTG VPSGSHFTNLIDSIICRILIKTFSLYCSIPISNLRTNGDDSAFHVYED YASDIILRAAGFFKEFFGMTINTDKSCVAGSPSEMHVSGTRWTGLRPT RSTQEWMMLAAYGETYSRIPFDSFQRLLGLGLSGGFGDSTFTRFFDYF QTGYDCRHGPNLLNWKKLRFLQQIFSIEELPLVYKQGAKTTLRLRLLV T

[0048] The following Examples are intended to illustrate but not limit embodiments of this disclosure.

EXAMPLE 1

[0049] The RdRp of PCV1, and all known encapsidated dsRNA viruses, is found in the virus particle so the analysis described in these Examples began by evaluating enzymatic activity using purified virus. This Example provides a description of preparing isolated virus.

[0050] The procedure was standard for plant viruses. The virus was purified from 50 g of plant tissue by homogenization of plant leaves in a blender with 50 ml of 0.1 M sodium phosphate buffer pH 7.4 containing 0.2 M KCl and 0.5% 2-mercaptoethanol, and 50 ml of chloroform. The resulting slurry was clarified by low speed centrifugation for 15 min. The aqueous portion was filtered through miracloth, and subjected to ultracentrifugation through a 10% sucrose cushion. The pellets were resuspended in sodium phosphate buffer and stirred overnight. The solution was clarified by low speed centrifugation, followed by a second ultracentrifugation as above. The final pellets were resuspended in sodium phosphate buffer and allowed to incubate at 4 C. overnight. The purified viral preparation was analyzed by 1% agarose gel in Tris-Glycine buffer (FIG. 1A). Short term storage of the purified virus was at 4 C.; for long term storage sterile glycerol was added to a final concentration of 50%, and the preparation was stored at 80 C.

EXAMPLE 2

[0051] This example provides a description of the RT activity of PCV1. Generating cDNA from dsRNA is not a straightforward reaction, because all known RT enzymes are only active on single-stranded RNA (ssRNA). Various strategies have been devised to use a dsRNA template, all of which require denaturing the dsRNA completely and adding chemicals, heat, and/or large amounts of oligonucleotides to maintain the template as ssRNA. Reactions are carried out at 42-55 C., temperatures that are well known in the art to be not optimal for RT enzymes. In particular, higher temperatures reduce the fidelity of the RT reaction (i.e. more errors are introduced in the cDNA sequence). In contrast, the present disclosure permits, as described above, cDNA generation at lower temperatures than have been previously possible, and without the use of denaturing chemicals.

[0052] To test the RT activity of PCV1, we replaced the MMuLV RT enzyme (commercially purchased from New England Biolabs) with the stored preparation of PCV1 in a cDNA reaction using the dsRNA of Zea mays chrysovirus 1 (ZMCV1) as a template. The reactions were adapted from standard protocols: dsRNA was mixed with a specific primer and boiled for 2 minutes, followed by rapid cooling on ice, addition of the enzyme, buffer, and dNTPs, and incubation on ice for 15 minutes. The MMuLV reaction was transferred to 42 C. for two hours, while the PCV1 reaction was held at room temperature for the same amount of time. At this temperature a normal RT enzyme would be unable to use dsRNA as a template because the RNA would have renatured. In a negative control, added water was used as the template along with PCV1 as RT enzyme.

[0053] Following the cDNA reaction, the samples were treated with 1 l (10 mg/ml) of boiled ribonuclease A (Sigma, USA), and incubated at room temperature for 15 min, to destroy remaining RNA. The samples were heated to 85 C. for 2 min, and the primers removed using a cycle pure kit (Omega, Bio-Tek, USA) according to the manufacturer's instructions. The samples were eluted in 30 l water. A 1.5 l aliquot of the cDNA was amplified by PCR in a standard reaction with the same primer used in the cDNA reaction, and forward primer specific for another region of the cDNA. The amplified cDNAs were separated on a 1.2% agarose gel, stained and visualized (FIG. 1B).

[0054] A second reaction was carried with another dsRNA virus, Curvularia protuberata thermal tolerance virus. In this reaction we added an additional sample, where the starting dsRNA and primer were not boiled. We obtained the same product with and without boiling the dsRNA, further substantiating that the PCV1 enzyme is indeed able to use dsRNA as a template.

[0055] Following our initial success we prepared a much larger virus isolation, using about 1 kg of plant tissue. This is not a rapid process, because it takes some time to grow the plants, and this needs to be performed in a growth chamber to prevent the risk of exposure to environmental pathogens that would complicate the results. We also performed a virus purification procedure on an isogenic line of Jalapeno that is virus free to provide a control to ensure that the activity was completely attributable to the virus. Because of the large volume we concentrated the plant extract using polyethylene glycol, a standard procedure in plant virus purification. However, this prep had no RT activity, and an EM showed particles that were highly aggregated (FIG. 2A). A third prep with another kg of plant tissue was accomplished, and in this case we restored activity and the virus particles look normal by EM, as shown in FIG. 2B.

EXAMPLE 3

[0056] This Example demonstrates recombinant production of an enzyme derived from PCV1 RdRp that exhibits RT activity. In particular, in order to avoid having to prepare virus from plants, the DNA sequence encoding the PCV1 RdRp was optimized for expression in E. coli and was cloned into a commercially available vector sold under the tradename pSUMO Vector. The sequence adds a 6 His Tag to the protein to facilitate purification, and small ubiquitin-like modifier (SUMO) that can be removed by protease digestion of the recombinant protein. The E. coli expression optimized DNA sequence is:

TABLE-US-00010 (SEQIDNO:112) GGTCTCAAGGTATGGTTCGTGGCACCCTGGTTGGCTATGATTACACCC AATTTCAAGGCGATCTGGTTAAAAGCACCCACCGTCACCCGCATGTTG TTCACCGTGAGATCGCGACCACCTACGTGGACCAGTACGCGTATGAGC ACATCGAAACCTTCAGCAGCCTGTATCCGGAGCTGATTCTGAAGGGTT GGAGCCGTAGCTACTATCTGCCGGAAAAACACCTGGCGGCGGTGCTGA ACTACAGCATGCCGAACGTTCCGGCGAGCCAGCTGAGCCAAAGCCTGT ATCGTCAGGCGATCGAGAGCGCGAAGAACGGCTTCATTAGCCTGCCGC GTGTGAAAGCGTTTGACGTTCTGACCGAAATGGATCAAGTTCCGTTTA AGAGCAGCAGCAGCGCGGGTTACAACTATACCGGTCGTAAAGGCCTGA TCGGTGATGAAAACCAACAGCCGTGCGATCAGCATTGCGAAGGCGGTG CTGTGGAGCGCGATTAAAGACGATGGCGAGGGCATCGAACACGTTATT CGTACCAGCGTGCCGGACGTTGGCTACACCCGTACCCAGCTGACCGAT CTGCTGGAGAAGACCAAAGTGCGTCAAGTTTGGGGCCGTGCGTTCCAC TACATCCTGCTGGAAGGTCTGGTGGCGTATCCGTTCATTCAGACCGTT ATGAGCCACAAGACCTTTATCCACGCGGGTCAAGACCCGCTGATTAGC GTGCCGCGTCTGCTGAGCGATGTTGCGCTGAACTGCAAATGGATCTAC AGCCTGGACTGGAGCCAGTTCGATGCGACCGTGAGCCGTTTCGAGATT CACGCGGCGTTTGACATCATTAAGAGCTACGTTGATTTTCCGAACTAC GAAACCGAACAGGCGTTCGAGATCACCCGTCAACTGTTTATTCACAAG AAAGTGGCGGTTCCGGACGGCTACATCTATGAAAGCCACAAAGGCATT CCGAGCGGTAGCTACTATACCAGCCTGGTGGGCAGCATCATTAACTAC CTGCGTATCAACTATCTGTGGCGTCTGCTGACCGGTCACCCGCCGCAG CAATGCCACACCCTGGGTGACGATAGCCTGGTGGGTGACAACAGCTAC GTTAACCCGCAGGCGATCGAGGAAGCGGCGAACAAGCTGGGCTGGCAC TTCAACCCGGATAAAACCCAATACAGCACCGTGCCGGAGGAAATCACC TTTCTGGGTCGTACCTATGTTGGTGGCCTGAACAAGCGTGATCTGACC AAATGCATTCGTCTGCTGGTGTACCCGGAGTATCCGGTTGAAAGCGGT CGTATCAGCGCGTACCGTGCGAAGAGCATTGCGCAAGACGCGGGTGGC CTGAGCGAAGTTCTGAACCGTATCGCGGATAAACTGCGTCGTATTTAT GGCACCGCGAGCGAAGAAGAAGTTCCGATTTATTTCAAGCGTTATGTT TTTGGCGTGTAA

[0057] The optimized sequence comprises modifications to remove tandem rare codons that can reduce the efficiency of translation or disengage ribosomes from the RNA, by changing

[0058] GC content to prolong mRNA half-life, to disrupt some predicted stem-loop structures, and to remove negative cis-acting sites.

[0059] High levels of expression of the protein in E. coli were induced and this expression was confirmed, as evidenced by FIG. 3. It is expected that improvements is solubilization of the protein can be achieved using a variety of known approaches in view of the present disclosure, including but not necessarily by moving the position of the histidine tag, and/or by expression in a different vector, such as pET26-Ub-CHIS which also utilizes a ubiquitin tag and has been used successfully for the expression of poliovirus RdRp as well as other viral polymerases.

EXAMPLE 4

[0060] This Example is illustrated by the results presented in FIG. 4. To obtain these results, RT-PCR products were produced using Zea mays chrysovirus 1 as a template, and primers for the RdRp gene. The following were used as reverse transcriptase: M, marker lane. 1, PCV1 virions; 2, PdPV-pa virions; 3, MMuLV RT (New England Biolabs). Expected size band is 500 nt (upper band in gel).

EXAMPLE 5

[0061] This Example is illustrated by the results presented in FIG. 4, lane 2. In this example we used virus particles from PdPV-pa, purified according to our published methods, in place of PCV1 virions in the above example with the Zea mays chrysovirus 1 template and primers. This reaction was carried out at room temperature, but the fungal host of PdPV-pa has a temperature optimum of 10 C. RT reactions at this temperature would like have extremely high fidelity. The amino acid sequence of PdPV-pa RdRp is provided as SEQ ID NO:2.

EXAMPLE 6

[0062] This Example is illustrated by the results presented in FIG. 5. To obtain these results, RT-PCR product from in vitro translated PCV1 RdRp was generated. This was performed using PCV1 dsRNA as template and primers for the RdRp gene. FIG. 5 has the following features: M, marker; 1, 1 l of in vitro translation product; 2, 2 l of in vitro translation product; 3, MMuLV RT (New England Biolabs).

[0063] While the disclosure has been particularly shown and described with reference to specific embodiments, it should be understood by those having skill in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the present disclosure as disclosed herein.